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Abstract 
The hematopoietic transcription factor c-Myb has been reported to be involved in diverse and 
important cellular functions such as differentiation, proliferation and apoptosis. It has also 
been implicated in tumorigenesis, and its viral counterpart v-Myb has been known to cause 
acute myelogenous leukemia in chickens. The biological mechanisms behind this oncogenic 
activation of c-Myb are not very well understood, and the list of target genes proposed for this 
transcription factor is at present too short to properly explain its biological function.  
 
In an effort to reveal some of the secrets of this elusive transcription factor we have 
established a new model system based on stable transfection of a human cell line with 
plasmids encoding three different versions of c-Myb: Full-length human c-Myb, a C-
terminally truncated version of human c-Myb designated c-Myb1-443 and v-MybAMV. By use of 
the Tet-On and Tet-Off gene regulation systems for the generation of these stably transfected 
cell lines the expression of c-Myb could be induced in a Dox-dependent fashion, allowing for 
superior reproducibility and control of gene expression compared to what can be obtained in 
model systems based on transient transfections.  
 
We succeeded in generating two Tet-On HEK293 cell lines with inducible expression of c-
Myb and v-MybAMV. These cell lines were employed in microarray experiments for the 
determination of potential target genes for these transcription factors. The preliminary results 
obtained from these experiments were in keeping with observations from other recent studies 
regarding microarray analyses of c-Myb: The activity of this transcription factor appears to be 
exceptionally context-specific, indicating that c-Myb is entirely dependent on the correct 
composition of cooperating factors and post-translational modifications in order to be able to 
fully exert its potential as a transcriptional activator. In addition it would appear that the 
truncations and mutations found in v-MybAMV result in a transcription factor whose activity 
differs from its cellular counterpart both in a quantitative and qualitative manner. 
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Chapter 1  Introduction 
1. Introduction 
1.1 Eukaryotic transcription factors  
Following the sequencing of the genomes of humans, Drosophila melanogaster, 
Caenorhabditis elegans and other model organisms, several previous notions regarding the 
correspondence between the complexity of an organism and the number of genes in their 
genome had to be re-evaluated. The numbers simply did not add up to the expectations, the 
differences were too small. The human genome was found to encode approximately 26 000 
genes, the C. elegans genome over 19 000 [1, 2]. It would appear that much of an organism’s 
complexity is not based so much on the number of genes as the manner in which the 
expression of these genes is regulated. Studies of the promoters of genes in yeast, nematodes, 
mice and humans indicate that the promoters and regulatory sequences in the genome (the cis-
elements) are generally more complex the further up on the evolutionary scale the organism 
is, and the arsenal of trans-acting factors found in higher eukaryotes also support the general 
idea that the mechanisms regulating gene transcription have evolved towards increasing 
complexity (reviewed in [3]). The general transcriptional machinery surrounding RNA 
polymerase II (Pol II) encompasses 200 to 300 different proteins, including the general 
transcription factors (GTFs), TBP-associated factors (TAFs), several chromatin remodeling 
complexes and other factors [4]. These proteins are found in all cells, as they form the basis of 
all Pol II transcriptional activity. The recruitment of this transcriptional machinery to specific 
promoters, the orchestration of gene regulation in a cell, is organized by another group of 
trans-acting factors: The site-specific transcription factors.  
 
Transcription factors constitute one of the largest groups of genes in the human genome. Out 
of a proposed 26 383 genes, of which the molecular function of 12 809 are unknown, 1850 
genes are assumed to encode transcription factors [1]. The transcription factors are 
characterized by the presence of two functional domains: A transactivation domain (TAD) 
and a DNA binding domain (DBD). The TADs are assumed to mediate interaction with co-
activators or parts of the basal transcription machinery. These domains may often have a high 
fraction of acidic residues or a specific amino acid (like proline, glutamine, serine or 
threonine), but are otherwise highly divergent in their structure and sequence [5]. 
Traditionally the transcription factors have been classified on the basis of their DBDs, though 
a different classification system, based on similarities in function rather than form has been 
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proposed [4]. This new classification system may be far more useful than the old one in most 
aspects, as there appears to be little correlation between the type of DNA binding motif and 
functional relationships, yet at present time there is but a small fraction of the transcription 
factors we know enough about to be able to classify them properly according to this new 
system. Some of the most common DNA binding motifs found are homeodomains, helix-
loop-helix domains (HLH), zinc-finger domains (Znf) and leucine-zippers (LZ). Depending 
on the type of DNA binding motif, some bind DNA as heterodimers, some as homodimers, 
yet others as monomers. The sequence specific DNA interaction is generally facilitated 
through van der Waals and hydrogen bonds between the major groove of the DNA helix and 
an α-helical structure in the DNA binding motif, in addition to interactions between the DNA 
backbone and other parts of the DBD of the transcription factor [6]. 
 
A DNA binding motif found in a large group of transcription factors, especially in plants, is 
the Myb domain. The founding member of this transcription factor family, c-Myb, has been 
the main subject of study for this thesis, and will be described further in the following 
chapters.  
 
 
1.2 The Myb family of transcription factors 
The Myb family of transcription factors is characterized by one, two or three repeats of the 
Myb domain, a highly conserved helix-turn-helix motif of approximately 50 amino acid 
residues (reviewed in [7-9]). The first Myb transcription factor to be identified was the protein 
product encoded by the transforming gene of the avian myeloblastosis virus (AMV), a 
retrovirus isolated in the 1930s, causing acute myelogenous leukemia in chicken. The gene 
was named v-myb, v for viral, myb from myeloblastosis. A version of this gene was also found 
in the E26 virus, an avian leukemia virus isolated in the 1960s and found to cause acute 
erythroblastosis in chickens. Through molecular cloning and DNA sequencing it was revealed 
that these two v-myb genes were fusion products including parts of a gene of cellular origin, 
an oncogene given the name of c-myb (cellular myb). AMV encodes a 45 kD transcription 
factor (v-MybAMV) composed of a C-terminally truncated version of c-Myb, with six amino 
acid residues encoded by the remains of the viral gag gene at the N-terminus, and eleven 
amino acid residues at the C-terminus from the viral env gene, in addition to ten amino acid 
substitutions relative to the c-Myb sequence, mainly in the DBD region. E26 encodes a gag-
 
2 
 
 
 
Chapter 1  Introduction 
Myb-Ets fusion product of 135 kD, v-MybE26. The Myb sequence of v-MybE26 is shorter than 
that found in the v-MybAMV, and has only one amino acid substitution relative to the c-Myb 
sequence (reviewed in [10]). The interest in c-Myb from the scientific community was in a 
large part based on these viral proteins and their strong connection to leukemic disease, and c-
Myb has been extensively studied over the past few decades. This transcription factor is 
further discussed in section 1.3. 
  
Vertebrates have two other three-repeat Myb transcription factors that carry significant 
homology with c-Myb beyond the DBD, named A-Myb and B-Myb, in addition to several 
more distantly related transcription factors with only one or two Myb-repeats. A-Myb is 
mainly expressed in male and female reproductive systems and in peripheral blood cells, 
whilst B-Myb appears to be ubiquitously expressed, with especially high expression levels in 
rapidly proliferating cells [7, 11]. The 95 kD A-Myb is the least studied of these three Myb-
proteins, but knock-out studies in mice indicate that it plays a critical role in spermatogenesis 
and mammary gland development (reviewed in [7]). The 93 kD B-Myb is a growth-regulated 
gene involved in cell cycle regulation, apoptosis and cancer. It is assumed to be the ancestral 
progenitor of the vertebrate Myb family, as it carries the greatest resemblance to the single 
Myb found in invertebrates. Whereas knock-out studies for A-Myb showed viable mice, B-
Myb knock-out mice die at an early embryonic stage due to impaired inner cell mass 
formation (reviewed in [11]). 
 
In addition to these Myb proteins, vertebrates also have several other proteins with the Myb 
domains in their structure, but not all of these are transcriptional regulators. For example the 
telomere binding proteins TRF-1 and TRF-2 have a DBD that carries significant homology to 
the Myb domain, as does the Cyclin D interacting protein DMP1. In plants the two-repeat 
Myb (R2R3) family constitutes the largest group of transcription factors, and several three 
repeat Myb proteins have been found as well [12]. These transcription factors generally carry 
little homology to the vertebrate three-repeat Myb proteins beyond the DBD, and are involved 
in diverse cellular functions (reviewed in [13, 14]).  
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1.3 c-Myb 
The human MYB gene has been located to chromosome 6, band q22-q23 [15-17], and encodes 
a 75 kD transcription factor of 640 amino acid residues, c-Myb. An alternative gene product 
of 89 kD has also been found in some tissues in human, mouse and chicken, the result of an 
alternative splice variant with an additional exon between exon 9 and 10, named exon 9A [18-
20]. The expression of c-myb is high in immature hematopoietic cells, but it is also reported to 
be expressed in colonic crypts and neurogenic zones of mice, in addition to smooth muscle 
cells, epidermis and melanocytes (reviewed in [21]). It has mainly been studied as a 
hematopoietic factor, as that was the context in which it was first discovered and brought 
about the most striking effects in knock-down/knock-out studies in mice [22, 23], but the field 
of research has lately expanded to include studies of other tissues where c-Myb has been 
found to be expressed.  
 
Though c-Myb has been the subject of intense study for more than two decades, and much has 
been revealed regarding its structure, post-translational modifications, interaction partners and 
some of its target genes, there are still many questions that have yet to be answered in order to 
fully understand how this transcription factor functions in a cellular context. This chapter will 
present some of the findings from past scientific studies regarding c-Myb structure, 
interaction partners and biological function.  
 
1.3.1 Functional domains 
Like other transcription factors, c-Myb has a modular structure with distinct functional 
domains separated by flexible linker sequences. The DBD of c-Myb is located near the N-
terminus, the TAD in the middle of the protein. In addition to these two functional domains, 
c-Myb also has a C-terminal region that appears to exert a negative regulatory function on 
transcriptional activation. This region has therefore been named the negative regulatory 
domain (NRD). 
 
DNA binding domain – DBD 
The DBD of c-Myb is comprised of three imperfect tandem repeats, designated R1, R2 and 
R3[7].  Each repeat is 51-52 amino acid residues long, and folds into three α-helices, of which 
the two C-terminal helices constitute an atypical helix-turn-helix (HTH) motif somewhat 
similar to that found in the homeodomain [24]. A marked feature of the repeats is the 
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recurrence of three tryptophan residues, each 18-19 amino acid residues apart [25]. These 
tryptophan residues are highly conserved in the DBD of Myb proteins from yeast to humans, 
and are found to be critical for DNA binding, forming a hydrophobic scaffold that stabilizes 
the HTH motif [26]. The latest crystal structure of the c-Myb DBD in complex with DNA 
confirmed the previous reports that only R2 and R3 form a direct contact with DNA, while R1 
appears to only mediate some stabilization of the protein-DNA complex through long-
distance electrostatic interactions [7, 27]. R2 and R3 recognize and bind to separate half sites 
of the functionally bipartite minimal Myb recognition element (MRE) 5’-YAAC[GN/NG]-3’ 
[28], lately extended to the optimal sequence 5’-NNCNTAACGGTTTTT-3’ [29]. The role of 
the R1 repeat is still largely unknown, but has been proposed to play a role in RNA binding 
[30]. 
 
Transactivation domain – TAD 
In human c-Myb the TAD has been located to the amino acid residues 275-327 [31], a stretch 
containing clusters of acidic residues, as is often observed for the TADs of eukaryotic 
transcription factors [5, 7]. There is still some uncertainties regarding the exact location of the 
TAD, as results have varied somewhat depending on the cell system used [8]. Interestingly, 
the transactivation ability does not appear to depend on the overall charge of the region [32]. 
The KIX domain of the transcriptional co-activator CREB binding protein (CBP) has been 
reported to interact with the TAD of c-Myb [33], and recently the solution structure of this 
complex was published, indicating that the minimal TAD forms an amphipathic helix upon 
binding to CBP, with a critical leucine residue inserted in a deep hydrophobic pocket of the 
KIX domain [34].  
 
Negative regulatory domain – NRD 
The first indications that the C-terminal region of c-Myb exerts a negative regulatory function 
on the activity of this transcription factor came from studies of the v-Myb proteins and other 
deletion products of c-Myb that displayed a marked increase in transcriptional activity 
compared to the full-length protein [32, 35]. The NRD is subject to several post-translational 
modifications (section 1.3.2) and is also found to mediate interactions with other proteins 
(section 1.3.3). The NRD encompasses several distinct regions that are highly conserved and 
assumed to mediate the negative regulatory function of the domain: A heptad leucine repeat 
(HLR) including a FAETL motif, a TPTPFK stretch (TP-domain, or conserved region (CR)) 
and SUMO-binding sites, in addition to several phosphorylation sites. The heptad leucine 
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repeat is proposed to form a leucine zipper motif [36, 37], functioning as a protein-interaction 
domain for co-regulators that exert a negative effect on c-Myb activity [38-40], and/or the 
formation of inactive c-Myb homodimers [41]. There is some discrepancy regarding the 
function of the HLR region and the FAETL motif, as these regions have also been reported to 
be vital for transactivation by v-Myb and thus considered to be part of the TAD, not the NRD 
[36, 42]. The leucine zipper motif is disrupted by the insertion of exon 9A in the p89 version 
of c-Myb. The TPTPFK stretch is conserved between all vertebrate Myb proteins, indicating 
that it plays an important role in the regulation of c-Myb, and is also subject to post-
translational modifications (section 1.3.2 and references therein).  
 
1.3.2 Post-translational modifications 
c-Myb is subject to a large variety of post-translational modifications, including 
phosphorylation, acetylation, ubiquitination, sumoylation and redox-regulation. These 
modifications regulate the interactions of c-Myb with other proteins, its activation potential, 
half-life and DNA binding ability.  
 
Phosphorylation
c-Myb has several potential phosphorylation sites, and many of these have been shown to be 
phosphorylated by kinases in vitro, a few also in vivo. In the N-terminal region serine 11 and 
12 have been reported to be phosphorylated both in vivo and in vitro by casein kinase II 
(CKII) or a kinase with similar activity [43]. The effect of this phosphorylation on c-Myb 
activity and DNA binding ability has been a matter of some dispute, some studies have 
reported increased DNA binding as a result of phosphorylation [43], others inhibition of DNA 
binding [44], some no effect at all [45]. The latest reports indicate that these serine residues 
are constitutively phosphorylated in endogenous c-Myb [46]. Serine 116 has been reported to 
be phosphorylated in vitro by cyclic AMP-dependent protein kinase A (PKA) or a similar 
kinase activity [43, 47], but the studies do not agree on the effect of this phosphorylation. It 
has been determined that the adjacent V117D mutation in v-MybAMV completely abolishes the 
phosphorylation of this serine residue [47]. The DBD has also been reported to be 
phosphorylated by the serine/threonine kinase Pim-1 in vitro [48], and the interaction with 
Pim-1 has been reported to enhance c-Myb transcriptional activity in a p100-dependent 
manner [49]. The C-terminal region is also rich in potential phoshorylation sites, and 
hyperphosphorylation of the NRD by HIPKII mediated by Wnt-1 signaling has been coupled 
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to degradation of c-Myb through the proteasome pathway [50]. Phosphorylation of serine 532 
is observed in several cell lines in vivo, and this residue has been shown to be phosphorylated 
by p42MAPK in vitro, a phosphorylation that may differentially regulate c-Myb activity on 
different promoters [51]. 
 
Acetylation 
Acetylation of the lysine residues K471, K480 and K485 in c-Myb has been reported to be 
mediated by the histone acetyltransferase p300 both in vivo and in vitro [52]. These lysines 
are conserved between frog, mouse, chicken and human c-Myb [52], and also among the Myb 
family members A-Myb and B-Myb [53, 54]. Two other lysine residues, K442 and K445, 
have also been shown to be acetylated by CBP/p300, and acetylation of these five lysines is 
reported to increase DNA binding and transactivation activity of c-Myb, probably by 
increasing c-Myb’s affinity for CBP [55].  
 
Ubiquitination 
The NRD of c-Myb has been reported to be subject to poly-ubiquitinylation, targeting c-Myb 
to degradation by the 26S proteasome [56, 57]. The same studies also reported that C-
terminally truncated versions of c-Myb, including v-Myb, appear to be more stable than wild-
type c-Myb.  
 
Sumoylation
c-Myb can be post-translationally modified by SUMO-1 (small ubiquitin-related modifier-1) 
on K503 and K527 within the EVES domain of NRD [58]. Stress-induced conjugation of the 
two other SUMO family members, SUMO-2 and -3, has also been reported, resulting in rapid 
inactivation of c-Myb [59]. Sumoylation of the two c-Myb sites by SUMO-1 is 
interdependent [60], and also results in reduced transactivational activity [58, 60]. 
Sumoylation of c-Myb is shown to be stimulated by TRAF7, leading to an increased fraction 
of c-Myb located in the cytoplasm, thereby negatively regulating its activity [61].  
 
Redox-regulation 
DNA binding by c-Myb is highly dependent on the redox state of a conserved cysteine in R2 
of the DBD, cysteine 130 [62]. Several reports have shown that oxidation of this residue has a 
severe negative effect on the DNA binding ability of c-Myb, possibly due to alterations in the 
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structure of R2 [45, 63, 64]. Interestingly, some of the mutations found in v-MybAMV result in 
decreased redox sensitivity [65], possibly contributing to its transformational activity.  
   
1.3.3 Interaction partners 
 c-Myb has been found to interact with several proteins, some of which cooperate with c-Myb 
in the regulation of gene expression at distinct promoters, others that regulate c-Myb activity 
directly (reviewed in [7, 66]). Most of these protein interacting factors have been found to 
bind to one of the highly conserved regions of c-Myb; DBD, TAD or NRD. This section will 
present some of the factors proposed to interact with the c-Myb protein, and the biological 
consequences of these interactions.  
 
Interactions with the DBD 
There are a large number of cellular factors that have been shown to interact with the DBD of 
c-Myb, indicating that this region has an important function as a “protein docking” domain in 
addition to its DNA binding function. One of the first cooperating transcription factors 
determined for c-Myb was C/EBPβ, or NF-M, which was found to cooperate with c-Myb in 
the activation of specific myeloid genes, including mim-1 [67]. C/EBPβ and its family 
members α, δ and ε play an important role in the regulation of hematopoietic development, 
making their connection to c-Myb quite interesting [68]. The biological relevance of the 
interaction determined between the co-activator p100 and c-Myb has been more unclear, as 
p100 is mainly a cytosolic protein [69], yet the results have been confirmed in other studies, 
and were further supported by the finding that p100 and the kinase Pim-1 interact with each 
other to enhance the transcriptional activity of c-Myb [49]. Pim-1 is also found to interact 
with the DBD of c-Myb and phosphorylate it [48], but the biological relevance of these 
interactions remains to be elucidated. Interaction between c-Myb and the histone H3 tail has 
been reported to be required for the p300 mediated acetylation of K18 and K23 of H3, a 
prerequisite for gene transcription [70]. Mutations in the v-MybAMV protein abolishes this 
interaction, indicating that v-MybAMV may play a dominant-negative role in the regulation of 
genes involved in differentiation, possibly explaining some of its oncogenic potential. 
Another factor that links c-Myb to chromatin is the chromatin remodeling factor Mi2α, 
recently found to interact with c-Myb as a co-activator of transcription [71]. Mi2α is reported 
to form part of the NuRD repressor complex, so the finding that it can act as a co-activator of 
c-Myb was somewhat unexpected, but it appears that Mi2α has two functions in 
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transcriptional regulation, a helicase-dependent repressor function and a helicase-independent 
activation function. Not only is c-Myb activity regulated by interactions with other proteins, 
c-Myb has also been reported to increase the activity of the heat-shock protein HSF3 in 
unstressed proliferating cells, creating a link between stress response by heat shock proteins 
and proliferation. The c-Myb induced activation of HSF3 is negatively regulated by p53, 
which blocks the c-Myb-HSF3 interaction by binding to HSF3 [72, 73]. 
 
In addition to these factors that function as co-activators of c-Myb regulated transcription, 
there are several factors that interact with the DBD of c-Myb that repress transcription by this 
transcription factor. Ski, N-CoR, and mSin3A are three co-repressors reported to bind to c-
Myb DBD in co-operation with TIF-1β, recruiting the histone deacetylase complex to c-Myb 
[74]. It was also observed that Ski competes with the co-activator CBP for c-Myb binding, 
and that mutations found in v-MybAMV weaken the interaction with these co-repressors. 
Another interaction where distinct differences between c-Myb and its viral counterpart have 
been observed is the interactions with the cyclins D1 and D2. Previous studies have reported 
that these cyclins inhibit the activity of v-Myb, but have little effect on c-Myb activity [75]. 
However, Lei et al. published in 2005 an article reporting that c-Myb activity is also inhibited 
by cyclin D1, contradicting these previous findings [76]. Cyp40 is a cyclophilin reported to 
negatively regulate c-Myb, but is unable to bind v-Myb due to the mutation of the binding 
site, thus evading another potential regulatory mechanism [77]. RARα and c-Maf are 
transcription factors involved in promoting differentiation, and are both shown to inhibit 
transcriptional activation by c-Myb (reviewed in [66]). Another factor linking c-Myb to 
regulation of differentiation is MyoD, a key regulator of myogenesis found to be repressed by 
direct interaction with c-Myb [78]. 
 
Interactions with the TAD and NRD 
CREB-binding protein (CBP) and p300 are closely related co-activators that are ubiquitously 
expressed, have histone-acetyl transferase activity and are presumed to play a vital part in 
cellular processes such as growth and development, in addition to being implicated in 
multiple malignancies (reviewed in [79, 80]). They interact with numerous transcription 
factors as well as transforming proteins, including c-Myb [33, 81]. This c-Myb interaction is 
reported to be constitutive, rather than phosphorylation dependent, and it has been shown in 
several studies that CBP or p300 are required for c-Myb transcriptional activity (reviewed in 
[66]). CBP and p300 are proposed to play a vital part in regulation of differentiation and 
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proliferation of hematopoietic cells [82], making their connection to c-Myb very interesting. 
PAX5/BSAP (B-cell lineage-specific activator protein) is reported to cooperate with c-Myb 
on activation of the RAG-2 promoter [83], probably in combination with LEF-1 [84], 
providing another link between c-Myb and gene regulation in hematopoietic cells.  
 
As has been observed for the proteins that interact with the DBD of c-Myb, there are 
interaction partners that interact with the TAD and NRD that are reported to repress c-Myb 
regulated transcription. Among these are the adenovirus E1A associated protein BS69 [85], 
the erythropoietin regulated Rcd1 [86], the AT motif-binding factor termed ATBF1 [40], 
TIF1β as mentioned above [74] and the nucleolar LZ protein p160 and its proteolytic 
fragment p67 [38].  
 
Intramolecular interactions 
The activity of c-Myb has been proposed to be regulated through intramolecular folding of the 
protein mediated by an interaction between the DBD and EVES motif [69], quite similar to 
the interaction between the DBD of c-Myb and an EVES motif found in p100. It has been 
proposed that this folding of c-Myb reduces its activity by blocking protein-protein 
interactions with co-activators and/or by obstructing DNA binding [66].  
 
1.3.4 Target genes  
Like other sequence specific transcription factors, c-Myb activates its target genes by binding 
to its recognition sequence (MRE) in the vicinity of the target gene promoter, so one should in 
theory be able to elucidate whether a gene is a potential c-Myb target simply by studying the 
regulatory sequences surrounding the gene. Unfortunately, the minimal MRE is very short, 
only six base pairs (bp) long, so it can be found in just about any random DNA sequence 
longer than 1 kb. Even so, some target genes for c-Myb have been found in this manner. At 
present, several target genes have been reported for c-Myb and its viral homologue v-Myb 
(reviewed in [7]), but activation by c-Myb of most of these proposed target genes has only 
been studied in reporter assays, not in resident chromosomal genes. In this section, only the 
target genes in the latter category will be discussed, whereas an extended list of proposed 
target genes for c-Myb and v-Myb is presented in table 1.  
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Gene Species Function RCG References 
MIM1 (mim-1) chicken Chemotactic factor/acetyltransferase Yes [87, 88] 
GBX2 human Transcription factor, hematopoiesis Yes [89] 
CD34 human Hematopoietic stem cell surface protein Yes [90, 91] 
LYZ (lysozyme) chicken Lysozyme, enzyme degrading bacterial cell walls Yes [67] 
TOM1 (tom-1) chicken Endofin binding partner Yes [92, 93] 
ADORA2B (A2B) chicken Adenosine receptor 2B, transmembrane Yes [94] 
Kit (c-kit) mouse Tyrosine kinase receptor Yes [95] 
PDCD4 (Pdcd4) chicken Possible tumor suppressor Yes? [96, 97] 
RAG2 human Part of the V(D)J recombinase, lymphoid Yes [83, 98] 
Igf1 (IGF-1) mouse Insulin-like growth factor I Yes [99, 100] 
MYC (c-myc) hu./mo. Transcription factor, proliferation-related Yes [101-104] 
BCL2 (Bcl2) human Anti-apoptotic regulatory protein Yes [105-108] 
COL1A2  human Type I collagen α2 chain, structural protein Yes [109] 
TCRD (TCRδ) human T-cell receptor δ, V(D)J recombination No [110, 111] 
TCRG (TCRγ) human T-cell receptor γ, V(D)J recombination No [112] 
CD4 human Cell surface receptor No [113, 114] 
ANPEP (CD13) human Alanyl aminopeptidase No [115] 
CDC2 (cdc2) human Cell cycle-related kinase No [116] 
ADA human Adenosine deaminase No [117] 
MYB (c-myb) human See section 1.3.5 No [118] 
LCK (lck type I) human Lymphoid-specific Src-family tyrosine kinase No [119] 
PAX6 quail Transcription factor, nervous system development No [120] 
Gata1 (GATA-1) mouse Transcription factor, hematopoiesis No [121] 
Ela2 (NE) mouse Neutrophil elastase, granule protein No [122, 123] 
PTGS2 (COX2) human Cyclooxygenase-2, prostaglandin metabolism No [124] 
TRHR human Thyrotropin-releasing hormone receptor No [125] 
WT1 human Transcription factor No [126] 
CHAT (hChAT) human Choline acetyltransferase, metabolism No [127] 
CCNA1 (Cyclin A1) human Cyclin A1, cell-cycle regulatory molecule No [128] 
MAT2A human Methionine adenosyltransferase No [129, 130] 
PRTN3 human Myeloblastin, serine protease, neutrophil No [131] 
KITLG (SCF) human Stem cell factor, hematopoietic No [132] 
 
Repressed genes     
ERBB2 (c-erbB2) human Tyrosine kinase receptor No [133] 
CSF1R (c-fms) hu./mo. Macrophage colony-stimulating factor receptor No [134] 
NRAS (N-ras) human Small GTPase, intracellular signaling No [135] 
CD4 human Cell surface receptor No [136] 
Igε GL human Ig epsilon germline, class switch recombination No [137] 
Table 1 Proposed target genes of c-Myb and/or v-Myb reported with stronger evidence than simple detection of 
Myb binding sites in the promoter. The cases where the resident chromosomal genes (RCG) have been shown to 
be activated by c-Myb/v-Myb are shown in the RCG-column. Repressed genes are shown in the lower part of the 
table. Gene names listed according to OMIM/OMIA annotation, with gene annotation from reference in 
brackets. Adapted from [138].  
 
The first Myb target gene to be identified was the chicken gene mim-1 gene [88], which 
encodes a myeloid specific protein of 326 amino acid residues designated P33 (or Myb-
induced myeloid protein 1, MIM1). It has been shown to be regulated by c-Myb and v-
MybE26, but not by v-MybAMV [67, 87]. The biological function of P33 is at present not 
entirely clear, but it has been reported to function as an acetyltransferase [139], and shows 
significant homology to the human neutrophil chemotactic factor LECT2 [140]. Gastrulin 
brain homeobox 2 (GBX2) is in contrast a gene that responds to activation by v-MybAMV in a 
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constitutive manner, but requires specific signaling events in addition to the presence of the 
co-activator C/EBP in order to be activated by c-Myb or v-MybE26 [89]. GBX2 encodes a 
transcription factor that acts as a regulator of the chicken myelomonocytic growth factor 
(cMGF), explaining how v-MybAMV can transform cells in a growth factor independent 
manner. The hematopoietic stem cell antigen CD34 has been reported to be regulated by c-
Myb at the endogenous level, providing another link between c-Myb and regulation of 
hematopoiesis [91].  
 
Several target genes for c-Myb and v-Myb have been determined by the use of a fusion 
protein between the estrogen receptor and v-Myb or a C-terminally truncated c-Myb, 
including the genes encoding chicken lysozyme (LYZ), the putative endofin binding partner 
known as target of Myb1 (tom-1), adenosine receptor 2B (A2B), mouse c-Kit (c-kit) and the 
possible tumor suppressor Pdcd4 (Pdcd4) (see table 1 for references). The determination of 
RAG2 as a c-Myb regulated gene provided an important link between c-Myb and V(D)J-
recombination in B and T lymphocytes, emphasizing the important role played by c-Myb in 
T-cell development. Other genes involved in V(D)J-recombination have also been proposed 
as c-Myb target genes, including the T-cell receptors γ and δ (table 1). The genes encoding 
insulin-like growth factor (IGF-1), the oncoprotein c-Myc (c-myc) and the anti-apoptotic 
factor Bcl-2 (Bcl2) have been reported to be regulated by c-Myb (references in table 1), 
linking this transcription factor to important cellular functions such as proliferation, 
tumorigenesis and apoptosis. COL1A2 is a gene encoding the alpha-2 polypeptide of collagen 
I, and has been reported to be activated by c-Myb, linking c-Myb to several fibrotic disorders 
[109].  
 
There has in recent years also been published three articles presenting the results from 
microarray-based gene expression assays used in combination with virus-based expression 
systems to determine target genes for c-Myb, v-Myb and the related Myb proteins A-Myb and 
B-Myb [141-143]. The most striking result reported in these articles is the lack of correlation 
in Myb regulated gene expression between different cell types; it would appear that c-Myb 
regulates a different set of genes in each cell type studied.  
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1.3.5 Biological role 
The interaction partners and proposed target genes for c-Myb and its viral counterparts have 
provided several links between this transcription factor and important biological functions 
such as proliferation, differentiation, apoptosis and tumorigenesis, and knock-out and knock-
down studies in combination with studies of the expression patterns of c-Myb have 
contributed with additional links to these cellular processes. Knock-out studies have shown 
that c-myb  null mice die within day 15 of gestation due to severe anemia after developing 
normally until day 13 [22], and knock-down studies in which the expression of c-myb was 
reduced to 5-10 % of wild-type level also confirmed that c-Myb plays a vital part in 
regulation of hematopoiesis [23]. However, c-myb is not only expressed in hematopoietic 
cells, but also in the neural retina [144, 145], lung epithelium [145], colon [146], aortic 
smooth muscle cells [147], thyroid and hair follicles [148], implying that this transcription 
factor has a distinct function in these tissues.  
 
The observation that expression of c-myb is high in immature proliferating cells of the 
hematopoietic system but is down-regulated upon terminal differentiation were the first 
indications that c-Myb plays an important role in the choice between proliferation and 
differentiation of these cell lines, findings that were supported by the observation that 
antisense inhibition of c-Myb led to blocked proliferation of several hematopoietic cell lines 
(reviewed in [7]). Later studies have revealed that low levels of c-Myb are sufficient for the 
expansion of progenitor cells, but the progression towards terminal differentiation is 
significantly altered in cells with sub-optimal levels of c-Myb [23], and disruption of the 
interaction between c-Myb and p300 led to a distinct block in T-cell, B-cell and red blood cell 
development while the number of hematopoietic stem cells increased significantly [149].  
 
The finding that expression of the anti-apoptotic factor Bcl-2 is regulated by c-Myb provided 
a link between c-Myb and apoptosis, and it has been shown that down-regulation of c-Myb is 
connected to decreased expression of Bcl-2 with resulting increased apoptosis [105-107]. 
Expression of a dominant-negative version of c-Myb in leukemic cells has also been shown to 
induce apoptosis in these cells, marking c-Myb as a potential candidate for gene therapy 
treatments of leukemic patients [150]. c-Myb has been implicated in a number of diseases, 
especially in the hematopoietic system, but also in epithelial cancers of the breast, colon and 
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gastro-oesophagus, and is considered to be an interesting target for anti-sense therapy for 
these malignancies (reviewed in [151]). 
 
 
1.4 Aims of the study 
Even though several target genes have been proposed for c-Myb, as described in section 1.3.4, 
this list of candidates is at present insufficient to explain the role played by this transcription 
factor in such important biological functions as differentiation and proliferation of the cells in 
which it is expressed. In previous years the methods available for determination of the target 
genes of a transcription factor have only allowed for the study of a single or a few targets at a 
time, but the development of high-throughput methods like microarray analysis has altered 
this, making it possible to study the expression of several thousand genes in a single 
experiment. However, the information value of such studies is entirely dependent on the 
model system used. The most common model systems that can be employed for such 
experiments are transient or stable transfections of cell lines without endogenous expression 
of the transcription factor of interest, or knock-down of the transcription factor by the use of 
siRNA in cell lines with endogenous expression.  
 
The main drawback with the use of transiently transfected cells is the variability of the cells 
under study and between experiments. Transfection efficiency can change from experiment to 
experiment and is usually significantly below 100 %, resulting in cell-to-cell variance. In 
addition, one has limited control over expression levels of the transcription factor, and it is 
difficult to use short expression times, so that one may discern direct from indirect effects. We 
therefore wished to generate a model system based on stable transfection of a human cell line 
with a gene regulation system allowing for the easy induction of c-myb expression. The 
choice of gene regulation system fell on the Tet-On and Tet-Off systems, in which the 
expression of the gene of interest is induced by the addition or removal of a tetracycline 
derivative from the growth medium, respectively (section 2.3.1).  
 
Previous studies have indicated that c-Myb’s viral counterpart v-MybAMV is not merely a 
more active version of c-Myb, but a transcription factor with a different set of target genes 
and distinct biological function. The truncated v-MybAMV with its mutations has proven to be 
a valuable tool for the study of c-Myb function, so we decided to not only generate cell lines 
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with inducible expression of c-myb, but also v-mybAMV and a truncated version of c-myb, 
designated c-myb1-443. c-Myb1-443 has the same C-terminal truncation relative to c-Myb as 
observed in v-MybAMV, but lacks the N-terminal truncation and the viral mutations. 
Comparison of the biological function of these three versions of c-Myb could provide an 
important insight in the molecular mechanisms behind oncogenic activation of c-Myb. 
 
The primary aim of this work thus became to generate and verify cell lines with inducible 
expression of c-myb and its derivatives v-mybAMV and c-myb1-443, which would provide a 
valuable model system not only in the present thesis but also for the laboratory group in 
further experiments beyond the scope of this study. The second aim was to employ these cell 
lines in preliminary microarray experiments with the object of determining new target genes 
for c-Myb and its viral counterpart v-MybAMV, in addition to studying whether the effect of a 
C-terminal deletion of c-Myb on gene expression is mainly quantitative or qualitative by 
comparison of the microarray results for cell lines with expression of c-Myb and c-Myb1-443. 
 
More specifically, the aims were: 
1. Generation and verification of stable cell lines with inducible expression of c-myb or 
its truncated counterparts v-mybAMV or c-myb1-443 for the study of c-Myb function and 
mechanisms responsible for oncogenic activation of this transcription factor.  
i. Construction of response plasmids. 
ii. Generation of double-stable cell lines. 
iii. Verification of double-stable cell lines. 
2. Utilization of the cell lines in preliminary microarray experiments to identify potential 
target genes of c-Myb, v-MybAMV and c-Myb1-443.  
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2. Materials and Methods 
This chapter describes the different methods used in the work on this thesis, providing a short 
introduction to the theoretic basis of each method and the protocol used. In those cases where 
commercial kits have been used, the protocol is provided by the supplier and will therefore 
not be described here, with a few exceptions. Unless otherwise stated, the information 
presented in this chapter is taken from the suppliers or “Molecular cloning: A laboratory 
manual” [152]. Solutions, kits and plasmid maps are listed in the appendix, as are web page 
addresses for the suppliers and collaborators.  
 
 
2.1 Bacterial methods 
The bacterial strain used for all experiments in this work was the DH5α strain of Escherichia 
coli (E. coli). All plasmids used carry an ampicillin resistance marker gene for selection of 
transformed bacteria.  
 
2.1.1 Growth and storage of bacteria 
Ideal growth environment for E. coli is in LB medium, at 37 °C, preferably under agitation. 
The medium is usually supplemented with an appropriate antibiotic; in this work only 
ampicillin was used. E. coli may be stored for prolonged periods of time at -80 °C in a 
solution of LB medium and 15 % glycerol.  
 
2.1.2 Preparation of competent E. coli  
Competent bacteria are cells that have been treated so as to be more susceptible to 
transformation, that is, they are more permeable for DNA from their surroundings.  Most 
methods used for generating competent bacteria are based on treating the cells with ice cold 
solutions of CaCl2 and divalent cations. DMSO and hexamine cobalt chloride have been 
known to further increase the competence of bacterial cells. In this work, the procedure 
published in an article by Inoue et al. in 1990 [153] was used to generate competent E. coli.  
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2.1.3 Transformation of E. coli 
Once bacteria have been made competent, they can be transformed with plasmids. A bacterial 
replication origo in the plasmid will ensure the replication of the plasmid within a bacterial 
cell, thus providing a source of larger amounts of the plasmid. Transformation of bacteria 
with plasmids may also be used to express proteins of interest. The method used for 
transformation of E. coli in this work is one in which the uptake of plasmids is induced by 
submitting the bacteria to heat shock, as described in “Molecular cloning: A laboratory 
manual” [152]. 
 
 
2.2 General molecular biology techniques  
2.2.1 Isolation of plasmid DNA from bacterial cultures 
Depending on the amount of plasmid DNA needed, two different kits were used in this work 
to isolate plasmids from E. coli. “GFX Micro Plasmid Prep Kit” from Amersham was used for 
isolating smaller amounts of DNA, “Genopure Plasmid Maxi Kit” from Roche for the larger 
amounts needed for purposes such as transfection of mammalian cells.  Both kits are based on 
alkaline lysis of the bacterial cells, precipitation of chromosomal DNA and proteins, followed 
by column purification of the plasmid DNA from the supernatant. The experimental 
procedures are described in the user manuals of the kits.  
 
2.2.2 Polymerase chain reaction (PCR) 
PCR is an exceptionally efficient, yet simple method for amplifying specific DNA sequences. 
Two oligos that are complimentary to the 3’ends of short stretches of DNA flanking the 
sequence to be amplified are used as primers for DNA synthesis by a thermostable 
polymerase. By raising the temperature, the template is denatured, allowing for the annealing 
of the primers to the template strand once the temperature is lowered. The annealing 
temperature is determined by the sequence and length of the primers. The temperature is then 
raised to the ideal temperature for the polymerase, and the elongation is allowed to proceed 
for a time determined by the length of the amplification product. Through repeating cycles of 
template denaturation, primer annealing and elongation, with the amplified product acting as 
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templates for new copies, an exponential increase in the number of specific DNA fragments is 
achieved.  
 
Procedure
The components listed in table 2 were mixed in a PCR-tube to a total volume of 100 µl, with 
the exception of the polymerase that was added after the first denaturation step of the PCR 
cycle, a 5 minute denaturation at 94 °C. For the PCR program a total of 30 cycles were run of 
denaturation for 30 seconds at 94 °C, annealing for 30 seconds at 55°C (determined by the 
melting temperature of the primers), then elongation for 1 minute and 30 seconds (determined 
by the length of the PCR product) at 72 °C.  
 Final
H2O -
BSA 1x
10x Thermopol buffer 1x
dNTPs (5 mM) 0.25 mM
Template 0.1 µg
Forward primer  1 µM
Reverse primer  1 µM
Vent DNA polymerase  1 U
Table 2 Components of a typical PCR reaction.  
 
2.2.3 Agarose gel electrophoresis 
Agarose is a linear polysaccharide that can be used to form gels with a pore size in the region 
of 100-300 nm, depending on the agarose concentration. The most commonly used 
concentration is 0.9-1 %, with a separation range of 0.5 to 7 kb. DNA fragments are 
visualized by staining the gel with ethidium bromide (EtBr) and viewing it in UV light. EtBr 
intercalates between the DNA base pairs of double stranded DNA, displaying orange 
fluorescence in UV light. In this work, all agarose gel electrophoresis was performed with a 
voltage of 100 V, in TAE electrophoresis buffer.  
  
2.2.4 Isolation of DNA from agarose gel 
The “GFX PCR DNA and Gel Band Purification Kit” from Amersham was used to isolate 
DNA fragments from agarose gels. The experimental procedure and theoretic background is 
described in the user manual. 
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2.2.5 Restriction enzyme digestion  
Restriction endonucleases are enzymes that bind to DNA in a sequence specific fashion, and 
create a double stranded cut at or near that sequence. There are three groups of restriction 
endonucleases found, of which the most commonly used in the laboratory are the group II 
enzymes, as these always create the cut in the DNA in the same place relative to the 
recognition sequence. The recognition sequence is four to eight bp long, and is usually 
palindromic. Some restriction enzymes create cuts with either 5’ or 3’ end overhangs, so-
called sticky ends, whereas others cut both DNA strands at the same place, creating blunt 
ends. The optimal conditions for each enzyme vary with regard to salt concentration, 
temperature and more, and can be found listed in the catalogues from the suppliers. The 
enzymes used in this work are listed in the appendix, as are the buffers used for each enzyme. 
 
2.2.6 Ligation of DNA fragments 
Bacteriophage T4 DNA ligase is an enzyme that catalyses the formation of phosphodiester 
bonds between adjacent 3’-hydroxyl and 5’-phosphate termini in DNA, using ATP as 
substrate. It is commonly used to ligate the DNA strands following restriction enzyme 
digestion in subcloning experiments. The enzyme is much more efficient at ligating sticky 
ends than blunt ends. The reactions involving blunt ends were therefore incubated over night, 
whereas the sticky ends were given a reaction time of only an hour.  
 
2.2.7 Spectrophotometric quantification of nucleic acids 
Purine and pyrimidine rings of nucleic acids absorb UV light, with a peak in absorption at 260 
nm. With a spectrophotometric reading at this wavelength the amount of RNA or DNA in a 
solution can be measured. An OD260nm of 1 measured by a standardized spectrophotometer 
corresponds to 50 µg/ml DNA, 40 µg/ml RNA or 37 µg/ml ssDNA. The purity of the nucleic 
acid solution can also be measured by comparing the absorption at 260 and 280 nm, as 
contaminating protein will give a strong absorbance at 280 nm due to their threonine and 
tryptophane side chains. A pure solution of DNA should have an A260nm/A280nm ratio of 1.8, a 
pure solution of RNA a ratio of 2.0. In this work, the spectrophotometer NanoDrop ND-1000 
was used for measuring the concentration and purity of RNA and DNA solutions.  
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2.2.8 DNA sequencing 
When using PCR amplification, there is always a risk of generating sequences with erroneous 
incorporation of nucleotides. Such PCR based mutations are most easily found by sequencing 
the section of the plasmid that includes the PCR amplified sequence. All DNA sequencing 
performed in the course of this work was done by the staff at the MegaBACE lab at UiO (now 
known as the ABI-lab). The sequencing instruments from Applied Biosciences used in this 
lab are based on capillary electrophoresis in combination with the dideoxy chain termination 
method with fluorescently labeled dideoxy nucleotides.   
 
 
2.3 Mammalian cells 
2.3.1 Tet-On and Tet-Off gene regulation systems 
There are several gene regulation systems on the market that can be used for generating stably 
transfected cell lines with inducible expression of a gene of interest, two of which are the Tet-
On and Tet-Off gene regulation systems from Clontech/BD Biosciences.  This system is 
based on the E. coli Tet repressor protein (TetR), a protein that in the absence of the antibiotic 
tetracycline binds to tet operator sequences (tetO) and represses the transcription of the genes 
of the tetracycline-resistance operon on the Tn10 transposon.  
 
The first part in the generation of a functioning Tet system is the stable transfection of a cell 
line with a plasmid encoding the regulatory protein. In the Tet-Off system, the regulatory 
protein is a fusion of the 207 N-terminal amino acids of the TetR protein and the 127 C-
terminal amino acids of the VP16 activation domain from the Herpes simplex virus, resulting 
in a tetracycline controlled transactivator (tTA). The Tet-On system uses a slightly modified 
version of the tTA, known as reverse tTA (rtTA), in which four amino acids have been altered 
so that the protein binds to the tetO in the presence of doxycyline (Dox), a tetracycline 
derivative, whereas tTA binds in the absence of tetracycline or Dox. Whereas tTA is 
responsive to both tetracycline and Dox, rtTA is only responsive to Dox, not tetracycline. 
Both regulator plasmids (pTet-Off and pTet-On) also carry a geneticin resistance marker gene 
for selection of stable transfectants.  
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The second part of the Tet system is the integration of a response plasmid (pTRE2hyg) 
encoding the gene of interest (Gene X) under the control of a tetracycline-response element 
(TRE). The TRE is composed of seven direct repeats of the 42 bp sequence containing the 
tetO just upstream of the minimal CMV promoter (PminCMV). A double stable cell line 
containing both the regulatory plasmid pTet-Off and the response plasmid encoding Gene X 
will then express Gene X when Dox is removed from the cell culture medium, whereas a 
double stable cell line with pTet-On as the regulatory plasmid will express Gene X in the 
presence of Dox in the medium. The response plasmid also contains a hygromycin resistance 
gene, to allow for selection of stable transfectants.   
 
2.3.2 Growth and storage of HEK293 cells 
HEK293 (ATCC number CRL-1573) is a cell line derived from human embryonic kidney 
cells. They have an epithelial morphology, and fall into the category of adherent growing 
cells, though they generally adhere only weakly to the growth surface. Tet-Off and Tet-On 
HEK293 cell lines express the tTA and rtTA, respectively. These were the cell lines used to 
generate double-stable cell lines with inducible expression of Myb proteins in this work. 
 
Procedure
Frozen stocks of cells were stored in cryotubes in liquid nitrogen vapor. Cells were thawed 
quickly by stirring the vial gently in 37 °C water, then transferred to a 75 cm3 flask containing 
5 ml of preheated growth medium. An additional 10 ml of medium was added before the cells 
were incubated in a humidified growth chamber at 37 °C, with an atmosphere of 5 % CO2. 
The growth medium was replaced once the cells had adhered sufficiently to the flask. In 
general, this was done the next day. Medium was then replaced at least every four days or 
when deemed necessary as determined by the color of the medium. Antibiotics were added to 
the medium 24-48 hours after seeding, geneticin to all Tet-On and Tet-Off cells, hygromycin 
only to the double-stable cell lines. Dox was added to the double-stable Tet-Off cells every 48 
hours. Once the cells reached ~80 % confluence, they were treated with trypsine/EDTA and 
split as necessary (generally, 1:4 or 1:8 under normal growth conditions).  
 
New stocks of cells were frozen down at an early passage. The cells were treated with 
trypsine/EDTA, trypsine was inactivated by the addition of growth medium (twice the volume 
of trypsine/EDTA used), then transferred to 15 ml tubes and centrifuged at 4 °C, 900 rpm for 
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5 minutes. The pellet was dissolved in a solution of 90 % FBS, 10 % DMSO to a minimum 
cell concentration of 1x106 cells per ml. The cell suspension was transferred to cryotubes, 1 
ml per tube, and frozen slowly down in an isopropanol container at -80 °C overnight, before 
they were placed in liquid nitrogen for long term storage.  
 
2.3.3 Counting cells – Determination of cell concentration 
To assess the cell concentration in a solution, the Neubauer Improved counting chamber was 
used. Each main square of the chamber contains 10-4 ml of medium; thereby the number of 
cells per ml can be obtained by counting the cells per chamber. As generally only the number 
of living cells are of interest, the cell solution is first diluted 1:1 with trypan blue, a dye that 
only colors the dead cells blue.  
 
Procedure
The cells were treated with trypsine/EDTA, medium was added to inactivate the trypsine, and 
a small aliquot of the cell suspension was transferred to an eppendorf tube. 50 µl of the 
aliquot was mixed with 50 µl trypan blue, and a small amount of this solution was then 
applied beneath a cover slide on the counting chamber. At least 100 cells were counted. 
Number of cells per ml medium = (Dilution factor*Average number of cells per square)
(10-4 ml per square) 
 
2.3.4 Transfection of HEK293 cells by use of Lipofectamine 
Transfection of mammalian cells is the equivalent of transformation of bacteria, which is the 
uptake of DNA from the cell’s surroundings. Several methods have been designed for this 
purpose; the most commonly used are electrophoration or different lipid solutions. 
Lipofectamine (Invitrogen) is a solution of two different lipids that form liposomal structures 
around DNA, thus enabling the passage of DNA through the cell membrane.  
 
Procedure
Transfections were performed on cells growing both in six-well plates (35 mm wells) and in 
10 cm plates. The amount of cells, medium, DNA and Lipofectamine used per well/plate are 
listed in table 3.  
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 35 mm well 10 cm plate
Cells 2x105 1x106
Growth medium 1 ml 9 ml
DNA 1.25 µg 10 µg
Opti-MEM 100 µl 900 µl
Lipofectamine 5 µl 40 µl
Opti-MEM 100 µl 900 µl
Table 3 Amount of cells, growth medium, DNA and Lipofectamine per well/plate of cells to be transfected. 
DNA and Lipofectamine were diluted in Opti-MEM medium separately before they were mixed for the final 
transfection solution. For transfection of multiple wells/plates, a mastermix was made. 
 
The cells were seeded out the day before transfection. Just prior to the transfection the growth 
medium was replaced by fresh medium without antibiotics. DNA and Opti-MEM were gently 
mixed and then incubated for 5 minutes at RT, as was Lipofectamine and Opti-MEM. 
Following incubation, the Lipofectamine/Opti-MEM mixture was added to the DNA/Opti-
MEM mixture drop by drop. This solution was gently mixed and incubated for 20 minutes at 
RT. The solution was then carefully added to the growth medium of the cells and the cell 
plates were tilted a few times to blend the solutions together. The cells were placed in the 
growth chamber for four hours before the transfection medium was replaced by normal 
growth medium with added antibiotics. The cells were harvested 24-48 hours post transfection 
and potential induction, or in the case of generating stable transfectants, split and seeded out 
on new 10 cm plates.  
 
2.3.5 Transfection of HEK293 cells by use of FuGENE 6 
FuGENE 6 (Roche) is a transfection reagent composed of lipids and several other 
components. Contrary to Lipofectamine, it does not form liposomes, but a multicomponent 
DNA complex that can be transported through the cell membrane. In this work, it was used to 
transfect cells for luciferase assays (section 2.4.6). 
 
Procedure
The day prior to transfection, cells were seeded out in six-well plates, 2x105 cells in 2 ml 
medium per well. A mastermix was made of 2 µl of FuGENE and 48 µl of medium (DMEM 
without any additives) per well to be transfected. FuGENE was added very carefully to the 
medium. The solution was gently mixed and incubated for 5 minutes at RT. DNA was then 
added to the FuGENE/medium mixture, 1 µg of DNA per well to be transfected. The solution 
was incubated for 30 minutes at RT before it was added to the cells, 50 µl solution per well. 
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The cells were incubated with the transfection medium for 4 hours at 37 °C, 5 % CO2 before 
the medium was replaced by normal growth medium with selective antibiotics. 1 µg/ml Dox 
was at this time also added to the medium for induction of Myb expression. Cells were 
harvested as described in section 2.4.6 16 hours after addition of Dox.  
 
2.3.6 Generation of stable transfectants 
Once a mammalian cell has taken up a plasmid, it will usually discard the plasmid within a 
few days, that is, the transfection is only temporary, or transient. However, a small number of 
transfected cells will integrate the plasmid into their own genome, making the transfection 
stable. By growing the cells in the presence of an antibiotic against which the plasmid 
encodes a resistance gene, one can select out these few stable transfectants, as they will 
survive whilst the transient transfectants will lose their resistance and die once they discard 
the plasmid. When allowed to grow, the stable transfectants will form separate colonies of cell 
clones, which can be isolated and then allowed to reproduce themselves in separate cell 
cultures. There are several methods that can be used for isolating separate clones. One of the 
simplest is using Cloning Discs (Sigma-Aldrich), paper discs with a diameter of 5 mm, 
soaked in trypsine/EDTA. As the trypsine breaks down the extracellular matrix binding the 
cells to the plate surface and each other, the cells will get soaked into the paper disc, and can 
then be transferred to separate wells in a 24-well plate.  
 
Procedure
HEK293 Tet-On and Tet-Off cells were seeded out in 10 cm plates and transfected by the use 
of Lipofectamine as described in section 2.3.4. Prior to transfection each of the plasmids were 
linearized with restriction enzymes to avoid disruptions of gene or promoter sequences caused 
by random linearization before insertion into the cellular genome. Linearized plasmids were 
purified by ethanol precipitation and dissolved in TE-buffer before transfection. 
 
The day after transfection the cells were split 1:20 and seeded out in new 10 cm plates, five 
plates per construct, resulting in a total of 30 10 cm plates. 48 hours after transfection 
hygromycin was added to the medium to a final concentration of 100 µg/ml. The medium was 
replaced every four days, with 1 µg/ml Dox added to the medium of the Tet-Off cells every 
48 hours. After three weeks, separate clones were isolated and transferred to 24-well plates 
using Cloning Discs, with 1 ml medium in each well. For each construct a total of 24 clones 
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were isolated if possible. Five days after they were transferred to the 24-well plates, the cells 
were transferred to six-well plates. When the cells were nearly confluent they were transferred 
to 10 cm plates, and the hygromycin concentration in the medium was increased to 150 
µg/ml. When approaching confluence, the cells were frozen down in stock as described in 
section 2.3.2, with each plate yielding two cryotubes of cells.  
 
 
2.4 Protein techniques 
2.4.1 Isolation of cell lysate for MicroBCA and Western blotting 
The MicroBCA protein concentration measurements are very sensitive to reducing agents, so 
the lysis buffer used for the majority of the Western blots performed in this work should not 
contain any such agents. With these constraints in mind, RIPA-buffer in combination with 
sonication was used to lyse the isolated HEK293 cells. The method described here is only 
applicable on mammalian cells that attach loosely to the growth surface, as HEK293 cells do. 
 
Procedure 
Growth medium was removed, and 1 ml of PBS added to each well. Cells were flushed loose 
by pipetting, and the cell suspension transferred to 1.5 ml eppendorf tubes, which were then 
centrifuged at 13 000 rpm for 2 minutes.  PBS was removed, and the cell pellet lysed in 100 
µl RIPA-buffer with added protease inhibitor. The lysate was then sonicated a few seconds at 
the lowest intensity. The lysate can be stored for a few months at -80°C, and may need to be 
sonicated anew upon thawing.  
 
2.4.2 MicroBCA protein concentration measurement 
The BCA (bicinchoninic acid) method of protein concentration measurement is based on the 
colorimetric quantification of the purple-colored reaction product formed by the chelation of 
two BCA-molecules and one cuprous ion (Cu+1). Cu+1 is formed when Cu2+ is reduced by 
proteins in an alkaline environment, and the correlation between protein concentration and 
absorbance of the purple-colored reaction product is linear. In this work, the MicroBCA-kit 
from Pierce was used to measure protein concentrations of 2-40 µg/ml, with a standard curve 
in the range of 0-60 µg/ml. The procedure is described in the user manual of the kit.  
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2.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
Polyacrylamide gels are composed of long chains of acrylamide crosslinked by N,N’-
metylenebisacrylamide. The polymerization of acrylamide and N,N’-metylenebisacrylamide is 
induced by the addition of free radicals, usually ammonium persulfate (APS), and the free 
radical stabilizer N,N,N’,N’-tetramethylethylenediamine (TEMED) is also added to the gel 
mixture. The pore size of the gel is determined by the concentration of acrylamide and N,N’-
metylenebisacrylamide, and the ratio of these two. Polyacrylamide gels are most often used 
for the electrophoresis of proteins, where the migration of the proteins is determined by their 
size, structure and charge, as well as the pore size of the gel. By treating the proteins with the 
strong anionic detergent sodium dodecyl sulphate (SDS) in the presence of the reducing agent 
β-mercaptoethanol, all secondary structures of the proteins are removed, disulfide bridges are 
reduced, and the proteins are given a strong negative charge from the bound SDS. Under these 
conditions, the migration of the proteins will be approximately proportional to their molecular 
weight.  
 
Procedure
The gel slab of a 10 % polyacrylamide gel with an upper stacking gel was placed in an 
electrophoresis apparatus filled with electrophoresis buffer (1xSDS-PAGE), and all air 
bubbles beneath the gel were removed. The upper chamber was also filled with 1xSDS-
PAGE, and the wells of the gel were washed thoroughly with the buffer. To one well 10-15 µl 
of BioRAD Precision Plus Protein Standards was added, protein samples/cell lysates to the 
other wells of the gel. The electrophoresis was run at 25-30 mA for 2-3 hours, or until the 
marker had migrated at least 2/3 of the gel. 
 
2.4.4 Western blotting – Semidry 
Western blotting (also referred to as immunoblotting) is a method commonly used for the 
detection of specific proteins in cell lysates. Following a separation of the proteins by SDS-
PAGE, the proteins are transferred, by blotting, to a PVDF membrane or nitrocellulose filter 
which binds proteins tightly. The membrane is washed in a blocking solution containing 
nonspecific proteins to block excess absorption sites in the membrane. An antibody specific 
for the protein of interest is then added, binding to its specific target protein. The presence of 
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this primary antibody is visualized by incubating the membrane with a secondary antibody 
(specific for the primary antibody) conjugated to the enzyme horseradish peroxidase (HRP).  
HRP will in the presence of its substrate catalyze a reaction emitting light which can be 
detected on a photographic film. The membrane used in this work was Hybond-P and the 
detection kit ECL Plus kit, both from Amersham.  
 
Procedure
The SDS-polyacrylamide gel was cut to size, and the orientation marked by cutting off one 
corner of the gel. A piece of membrane (Hybond-P) was also cut to the same size as the gel, 
as were six sheets of 6 mm paper. The membrane was first soaked in methanol, then in 
plus(+) buffer. Three sheets of paper were soaked in plus(+) buffer, three in minus(-) buffer. 
The different sheets were then stacked on the anode of the blotting apparatus (TE 70 
SemiPhor Semi-Dry Transfer Unit, Amersham) in the following order: Three sheets of paper 
soaked in plus(+) buffer, membrane, gel and finally three sheets of paper soaked in minus(-) 
buffer. All air bubbles were removed, the lid (cathode) put on, and extra weight was put on 
the lid. The electrophoresis was run for an hour, with 1 mA per cm2 membrane and a 
maximum voltage of 50 V. The membrane was then fixated in methanol for 2 minutes, while 
the apparatus was washed with distilled water and left to dry.  
 
Optionally, the membrane may at this point have been dyed with Ponceau S. to control 
whether the blotting process had been satisfactory. Washing the membrane for 5 minutes in a 
Ponceau S. solution would dye the proteins in the membrane red, and excess color would be 
washed away with distilled water.  
 
The membrane was gently shaken in 1xTBS-T with milk for 30 minutes at RT to block all 
protein binding sites. The primary antibody was diluted to the optimized concentration in the 
amount of 1xTBS-T with milk that just covered the membrane, and the membrane was 
incubated in this solution for at least two hours at RT or overnight at 4 °C, with constant 
agitation. The membrane was then washed at least 3x20 minutes in 1xTBS-T with milk at RT. 
The HRP-conjugated secondary antibody was diluted in 1xTBS-T with milk to the optimized 
concentration, and the membrane was incubated in this solution for one hour at RT, with 
constant agitation. The membrane was then washed six times in 1xTBS-T, then for 20 
minutes in 1xTBS-T with constant agitation. The membrane was kept in 1xPBS until 
detection. 
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The procedure for the ECL Plus kit (Amersham) is described in the user manual.   
 
2.4.5 Stripping and reprobing Western blot membranes 
Occasionally, there may be need for stripping and reprobing Western blot membranes, 
whether to use a different antibody or a different concentration of the antibody previously 
used. The membrane is then washed at 50 °C in a stripping buffer for 30 minutes while under 
rotation, removing antibodies and detection solution, leaving the membrane ready for a new 
round of antibody incubation and detection. Due to the rather harsh process of stripping the 
membrane, which often removes some of the blotted protein from the membrane, one should 
not use this method for blots for quantitative analysis. The procedure is described in detail in 
the user manual of the ECL Plus kit from Amersham.  
 
2.4.6 Luciferase reporter gene assay 
Firefly luciferase is an enzyme that catalyzes the following reaction: 
 
The amount of light produced will give a measurement of the amount of luciferase expressed 
in the cells, and this can be measured by means of a luminometer. By constructing a vector 
where expression of the luciferase gene is under the control of a c-Myb responsive promoter 
(TRHR or 3xGG), the amount of luciferase will be determined by the activity of c-Myb in the 
cells, and the luminometer measurements will thereby give an indirect measurement of this 
activity.  
 
Procedure
The cells were seeded out and transfected with FuGENE 6 as described in section 2.3.5. 16 
hours after changing the medium, the cells were harvested. The medium was removed, the 
cells were washed in PBS, 1 ml per well. PBS was removed, and 250 µl of Passive lysis 
buffer was added to each well. The tray was then placed on a shaker for 10 minutes at RT. 
The lysates were transferred to 1.5 ml eppendorf tubes. 50 µl of lysate was mixed with 50 µl 
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of “Luciferase assay reagent” in a tube, which was then quickly placed in the luminometer for 
measurement of the luciferase activity.  
 
 
2.5 RNA techniques 
To avoid contamination of RNA samples by RNases or other contaminants that could disrupt 
the following analyses, special precautions were made. In addition to heeding general 
guidelines for working with RNA, such as using gloves at all times, the water used for all 
experiments with RNA was Molecular biology grade water from Eppendorf, the pipette tips 
were RNase/DNase free filter tips and only single-use sterile plastic equipment was used.  
 
2.5.1 Trizol RNA-isolation 
Trizol (Life Technologies/Invitrogen) is a solution consisting of phenol and guanidine 
isothiocyanate, used for the isolation of total RNA from cells and tissues. Upon addition of 
Trizol, the cells are lysed, and further addition of chloroform followed by centrifugation 
separates the solution into an upper aqueous phase and a lower organic phase, with RNA in 
the aqueous phase, proteins and DNA in the organic phase. RNA is precipitated from the 
aqueous phase using isopropanol. 
 
Procedure
Cells were seeded out on 15 cm plates two or three days prior to RNA isolation at a density so 
as to be 50-80% confluent upon harvesting. Dox was added to the medium to a final 
concentration of 1 µg/ml 8 or 24 hours before harvesting to induce expression of Tet-
regulated genes. On each plate the medium was removed before addition of 4 ml Trizol. The 
lysates were scraped together on each plate and then transferred to 15 ml tubes. To each tube 
0.8 ml of chloroform was added before the tubes were shaken vigorously for 15 seconds, and 
then incubated at RT for 3 minutes. The tubes were centrifuged 20 minutes at 3000 rpm, 4 °C 
in a swing-out rotor (JS-rotor), brakes turned off. The upper aqueous phase in each tube was 
transferred to four 1.5 ml eppendorf tubes, 600 µl per tube. To each tube 500 µl isopropanol 
was added, and the tubes were incubated for 30 minutes at RT to precipitate RNA. Following 
a 10 minute centrifugation at 14000 rpm and 4 °C the supernatants were removed, and the 
pellets washed in 1 ml 70% ethanol. The samples were centrifuged at 14000 rpm for 5 
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minutes at RT, ethanol was removed, and the pellets dried completely before they were 
dissolved in 20 µl of water each. The RNA samples were quickly frozen down and stored at -
80 °C. 
 
2.5.2 RNeasy – Purification of RNA 
Some methods, such as real-time RT PCR and microarray analysis, require a very high quality 
of RNA, one that is higher than that generally achieved by Trizol isolation. DNase treatment 
is of particular importance, as traces of genomic DNA can wreak havoc on the results of such 
methods. The kit used in this work for the purification of isolated RNA was the “RNeasy Mini 
Kit” in combination with the “RNase-Free DNase Set” (both from Qiagen). The kit is based 
on DNase treatment of the RNA sample on a silica-gel column, where RNA with a length 
greater than 200 bp is bound to the silica-gel while smaller RNA fragments and other sources 
of contamination are washed away before the bound RNA is eluted with water. The procedure 
is described in the user manual.  
 
2.5.3 Bioanalyzer – Determination of RNA quality 
RNA is quite susceptible to degradation, and one way to measure whether the total RNA has 
been degraded or not is to compare the amount of 28S and 18S ribosomal RNA in the test 
sample. In this work the Agilent 2100 Bioanalyzer with the kit “RNA 6000 Nano Assay” was 
used for this purpose. The system is based on electrophoresis of the samples through glass 
capillaries filled with a gel matrix, and fluorescence is used to detect the RNA components. 
The main perks of this method compared to traditional gel electrophoresis are the small 
amounts of RNA necessary, a shorter, simpler work procedure as well as better, more 
standardized data. In this work the RNA was analyzed after the RNeasy purification step 
described in section 2.5.2, with 12 samples per chip used. The procedure is described in the 
user manual of the kit.  
 
2.5.4 Real-time RT-PCR 
Conventional RT-PCR (reverse transcription PCR) is one of the most sensitive methods 
available for the detection of gene expression at the mRNA level, but it is also a complex 
technique, and how quantitative it can be is rather questionable. Some of these major 
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drawbacks have in recent years been overcome by the introduction of fluorescent techniques 
for the quantification of synthesized DNA during the PCR process in combination with the 
use of a thermal cycler with inherent detection instruments, resulting in the real-time (or 
kinetic) RT-PCR method (reviewed in [154]).  
 
In the first step of this method cDNA is synthesized from total RNA using a reverse 
transcriptase enzyme with oligo-dT as a primer. Depending on the nature of the experiment 
and the RNA sample, other primers can also be used, such as random hexamers or gene 
specific primers. In the second step of the process a PCR reaction is run with primers for the 
gene of interest, and for each PCR cycle the amount of synthesized DNA is measured by a 
fluorescent detector in the thermal cycler in which the PCR reaction is run. In this work the 
Lightcycler apparatus from Roche was used, in combination with the SYBR Green dye for 
quantification of double stranded DNA (dsDNA). The SYBR Green dye emits a strong green 
fluorescence when bound to dsDNA, but very little in its free form or when bound to ssDNA. 
Based on how many cycles are needed to reach a determined threshold level of synthesized 
DNA, and determination of the efficiency of the PCR reaction through the use of a standard 
curve based on dilutions of the original sample, the original amount of a specific mRNA in a 
sample may be determined. The measurement is always made relative to another DNA source, 
in this work the level of the housekeeping gene β-actin was used as a reference. The 
procedure is described in the user manual for the Lightcycler apparatus.  
 
 
2.6 Microarray analysis 
Though many people may think of microarray analysis only in terms of the microarrays used 
for transcriptional profiling, this is but one of many applications for the method principle. 
Since the first articles on DNA microarrays (for transcriptional profiling) were published in 
the mid-nineties, the microarray term now also embraces methods for studying proteins, DNA 
mapping, RNA/RNAi and more (reviewed in [155, 156]). In addition to new microarray based 
methods emerging, the use of the technology has also shown an exponential increase over the 
past decade. In 1995, a search for the word “microarray” in PubMed gave a list of only three 
articles, only one of which was an article on DNA microarrays [157]. In 2000, the number of 
articles for that year was 411. For 2005 the number had soared to 5029 articles, at this time 
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the term not only referring to DNA microarrays, but also protein microarrays and other 
microarray methods.  
 
In this work two different DNA microarray platforms were used; the Affymetrix system 
(section 2.6.1) and in-house spotted oligoarrays from the Norwegian Microarray Consortium 
(NMC) at Rikshospitalet-Radiumhospitalet Medical Center (RR MC) hybridized with Cy3 
and Cy5 labeled cDNA (section 2.6.2-2.6.4). These two methods are both for transcriptional 
profiling and share some of the same theoretic principle, but are very different when it comes 
down to the experimental procedure. They exemplify the most widely used types of DNA 
array manufacturing: The photolithographic method and deposition (spotting) of DNA 
fragments (oligos) on a glass slide.  
 
2.6.1 Affymetrix microarray system 
The Affymetrix GeneChip arrays are an example of so-called high-density microarrays. 
Rather than depositing DNA fragments in spots on a glass slide, as is done in the production 
of spotted arrays, the features on a GeneChip array are synthesized directly on the array, 
nucleotide by nucleotide. This process begins by coating a quartz wafer with a light sensitive 
coating compound, preventing coupling of nucleotides to the surface of the wafer. A 
photolithographic mask is then applied before the wafer is exposed to light, deprotecting the 
features that are to have the same nucleotide at this position. When the wafer at this point is 
subjected to a solution of for instance thymine, this nucleotide will be coupled to the wafer 
only at the features that have been deprotected, making the oligo at this feature one nucleotide 
longer. The nucleotides that are washed over the wafer carry their own light sensitive 
protection group, preventing coupling of new nucleotides to the oligo until it has been 
subjected to light. The wafer must be washed with all four nucleotides for each nucleotide 
added to the oligos on the entire wafer, giving a total of 4n cycles of deprotection and 
coupling for a wafer with oligos of n nucleotides length. Usually the oligos are 25-mers, 
resulting in a total of 100 cycles of deprotection and coupling per wafer [158]. The density of 
the features becomes very high with the use of this production method, and each wafer can be 
diced into tens or even hundreds of separate arrays, depending on the number of features 
required per array. The arrays also become far more uniform than arrays produced by the 
deposition method, allowing for a different form of hybridization of the samples to be studied. 
Rather than the two-color cross-hybridization used for the deposition arrays, where two 
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samples are hybridized on the same slide, the samples analyzed with high density microarrays 
are hybridized to separate arrays. This also allows for all samples to be coupled to the same 
dye, usually biotin, eliminating another source of variation.  
 
The Affymetrix GeneChip system is a completely closed system, requiring the use of 
Affymetrix scanners and computer programs for data analysis. In this work, RNA samples 
were delivered to the Affymetrix lab at Centre for Occupational and Environmental Medicine 
(SYM) at RR MC, now a part of the Microarray Core Facility (MACF) at RR MC, and all 
further work including the data analysis was done by graduate engineer Siv Haugen Tunheim 
at this lab. The array used was the Human Genome Focus Array, an array representing over 
8 500 human genes.  
 
2.6.2 FairPlay – Synthesis and labeling of cDNA 
There are two different methods that can be used for labeling cDNA with Cy3 or Cy5, either 
direct incorporation of the dyes by using Cy3- or Cy5-linked dUTP in the cDNA synthesis 
reaction, or indirect incorporation, in which the cDNA is synthesized using amino allyl linked 
dUTP and the dyes with a NHS-ester leaving group are chemically coupled to these modified 
nucleotides at a later step in the process. Though the indirect method is somewhat more 
laborious and time consuming, it does have some rather important preferential qualities when 
compared to the direct labeling method. The direct method struggles mainly with the large 
size of the Cy-dye molecules, which can lead to the reverse transcriptase struggling with the 
incorporation of them, thereby impeding the enzyme’s efficiency as well as causing a low 
incorporation rate of these dye-coupled dUTP nucleotides. There is also a significant 
difference in the molecular size of Cy3 and Cy5, a factor that may lead to a higher rate of 
incorporation of Cy3 compared to Cy5, as Cy3 is the smaller molecule. Both of these factors 
are avoided in the indirect labeling method, as the amino allyl groups are rather small, and the 
size difference between Cy3 and Cy5 is insignificant for the coupling reaction. The indirect 
method also uses less RNA than the direct labeling method (10-20 µg versus 20-100 µg). The 
indirect labeling kit used in this work was the FairPlay II Microarray Labeling Kit from 
Stratagene, with NHS-ester containing Cy3 and Cy5 dyes from Amersham. Several minor 
tweaks were made to the procedure compared to the one given in the instruction manual of the 
kit. The procedure is therefore described in full below.  
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Procedure 
cDNA synthesis 
A single labeling reaction does not always produce sufficient labeled cDNA for slide 
hybridization, so two parallel labeling reactions were performed for each slide, giving a total 
of four labeling reactions per slide.  
1) 10 µg total RNA was dissolved in water to a total volume of 12 µl in a 0.5 ml PCR 
tube.  
2) 1 µl 500 ng/µl oligonucleotide d(T)12-18 was added. The solution was incubated at 70 
°C for 10 minutes, and then cooled on ice. 
3) A master mix was made of the following components (volumes are for a single 
reaction) in a PCR tube: 
2 µl 10x StrataScript reaction buffer 
1.5 µl 0.1 M DTT 
1 µl 20x dNTP mix 
0.5 µl RNase Block (40 U/µl) 
4) 5 µl of the master mix from step 3 was added to each of the RNA tubes from step 2. 
The tubes were given a brief spin to collect the contents. 
5) 3 µl StrataScript HC RT was added to each tube, and the tubes were incubated at 42 
°C for 120 minutes (in a PCR machine to ensure constant temperature).  
6) 10 µl 1 M NaOH was added to each tube. The tubes were then incubated at 70 °C for 
10 minutes to hydrolyze RNA. The 1 M NaOH was made fresh for each day of 
labeling by dilution of a 10 M NaOH solution.  
7) The samples were cooled slowly to RT (important not to place the samples on ice), 
and were then given a quick spin.  
8) 10 µl 1 M HCl was added to each tube to neutralize the solution.  
9) The samples were transferred from the PCR tubes to clear 1.5 ml eppendorf tubes.  
 
cDNA purification 
10)  4.8 µl 2.5 M sodium acetate, pH 4.5 was added to each tube. 
11)  1 µl 20 mg/ml glycogen was added. 
12)  100 µl ice-cold 95% EtOH was added. 
13)  The tubes were incubated at -20 °C for at least 30 minutes, usually overnight. The 
samples may at this point of the labeling reaction be stored for up to two months. 
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14)  Samples were spun down at 13-14 000 x g, 4 °C for 30-45 minutes. The supernatant 
was gently removed.  
15)  The pellet was washed in 0.5 ml ice-cold 70% EtOH, and then spun down for 15 
minutes at 13-14 000 x g, 4 °C. 
16)  The supernatant was gently removed with a pipette, the tubes were given a quick spin, 
and the last remnants of the supernatant were removed with the tip of a 10 µl pipette. 
The pellet was allowed to air dry until it had just turned translucent. Should the pellet 
overdry, it would be nearly impossible to dissolve it again. 
 
NHS-ester containing dye coupling reaction 
17)  The cDNA pellet was resuspended in 5 µl 2x coupling buffer and vortexed to mix. 
The buffer was incubated a short time at 37 °C before use, as it can form a precipitate 
at low temperatures. The cDNA solution was incubated at 37 °C for 15 minutes to aid 
in the resuspension process.  
18)  The fluorescent dyes were resuspended in 45 µl DMSO from the kit, and vortexed. 
Dye that would not be used the same day was dispensed into single use aliquots of 5 
µl in brown 1.5 ml eppendorf tubes and stored at -20 °C in the dark. When such 
aliquots were used, they were allowed to reach RT before the tubes were opened.  
19)  5 µl of dye was added to the dissolved cDNA pellet. The solution was mixed gently 
by pipetting.  
20)  The solution was incubated for 60 minutes at RT in the dark.  
 
Dye-coupled cDNA purification 
21)  90 µl of TE buffer was added to the labeled cDNA. 
22)  210 µl DNA binding solution was thoroughly mixed (vortexed) with 210 µl 70% 
EtOH per reaction.  
23)  200 µl of the mix from step 22 was added to the cDNA solution, which was then 
mixed by vortexing.  
24)  The solution from step 23 was transferred to a microspin cup seated in a 2 ml 
receptacle tube. The cap of the tube was snapped into place, and the tubes were spun 
down at maximum speed for 30 seconds. The cup was retained while the solution in 
the tube was discarded, then the cup was placed back into the tube.  
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25)  200 µl of the solution from step 22 was added to the cup, the cap of the tube was 
snapped into place, and the tubes were spun down for 30 seconds. The solution in the 
tube was discarded, the cup retained, and placed back into the empty tube.  
26)  750 µl 70% EtOH (washing buffer) was added to the cup. The tubes were spun down 
for 30 seconds, the washing buffer discarded. This washing step was performed twice.  
27)  The cup was placed back into the tube, which was then spun down for 30 seconds to 
remove any last remnants of washing buffer. 
28)  The cup was transferred to a clean 1.5 ml eppendorf tube, the receptacle tube was 
discarded.  
29)  50 µl of 10 mM Tris, pH 8.5 was carefully added to the fiber matrix of the cup. After 
5 minutes incubation at RT, the tube was spun down for 30 seconds at full speed.  
30)  The elution from step 29 was reapplied to the fiber matrix, incubated for 5 minutes at 
RT and spun down for 30 seconds. This step was repeated so that the buffer with the 
labeled cDNA was eluted through the matrix a total of three times.  
 
Analysis of labeled cDNA 
31)  The labeled cDNA was analyzed using the NanoDrop ND-1000 spectrophotometer 
described in section 2.2.7. This spectrophotometer has a separate function for 
microarray samples, one that gives a measurement of the amount of cDNA as well as 
incorporated Cy3 and Cy5 from a sample of 1-2 µl. For each slide 600 ng of Cy3- and 
Cy5-labeled cDNA was used, corresponding to 20-60 pmol of dye.  
 
Concentration of labeled cDNA 
32)  The 600 ng samples of Cy3- and Cy5-labeled cDNA from step 31 were mixed 
together, and the solution was concentrated to 59 µl using a SpeedVac vacuum 
centrifuge.  
 
2.6.3 Oligoarrays – Hybridization, wash and scanning 
The oligoarray type used in this work was the 21K human oligonucleotide array v2.3, 
produced by the NMC group at RR MC. These arrays are Corning GAPS2 glass slides spotted 
with oligonucleotides with a length of approximately 70 bp (70-mers) from the AROS Human 
oligo v2.0 set from OPERON. This gene set represents 21.521 human genes (UniGene 
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clusters). In addition to the gene spots, there are also several different types of validation 
spots, as well as some empty spots, giving a total of 23 232 spots per slide.  
 
Prehybridization of the slide is a method for minimizing background, and must be optimized 
for the slide surface and printing method used in the production of the array. Reactive groups 
on the slide surface are inactivated to suppress background, unbound DNA from the printing 
process is washed away, and the remaining DNA on the slide surface is denatured. Large 
amounts of BSA are generally used to block any reactive groups on the slide surface. 
 
There are several methods that can be used for hybridization of the slide, in this work both 
manual and automated hybridization were tried out, but only the results from the automated 
hybridization station were used.  
 
In this work the prehybridization of the slides, hybridization, wash and scanning was 
performed by the NMC division at RR MC due to difficulties with the hybridization station at 
our lab. The labeled cDNA was delivered after being concentrated to a volume of 59 µl as 
described in section 2.6.2. The scanned images were received the following day, ready for 
data analysis.  
 
2.6.4 Software analysis of microarray data with GenePix and BASE 
Microarrays generate huge amounts of data, and in order to make these data comprehensible 
and useful specialized software is needed. Different programs may be used for this purpose; in 
this work GenePix v6.0 and BASE v1.2 were used. 
 
First the scanned images must be linked to their respective GAL-files, files that give 
information on the identity of each spot on the slide. Then flawed spots must be flagged, 
whether the flaws are the results of wrong morphology, dust particles, salt residues or due to 
other reasons. This was all done in GenePix. The resulting data set was used to create a GPR 
file, a file that contains all the necessary information for further data analysis, which is the 
intensity, diameter, etc for each spot as well as the spot identity.  
 
BASE (BioArray Software Environment) is a database wherein one can store not just the 
scanned images and resulting data from them, but also all other relevant information from the 
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microarray experiments performed, such as RNA isolation and labeling method used. The 
database allows for the upload of several slide images with their respective GPR files into a 
single experiment, so that the information from multiple hybridizations may be compared and 
analyzed together [159]. The processing of the microarray data in this work was done 
according to the recommendations from NMC, as described below, with Lowess 
normalization used to correct for systematic differences in Cy3 and Cy5 intensities [160].  
 
Procedure 
The following list represents the filtering options used in the BASE analysis of the microarray 
experiments performed in this work. The spot filters used ensure that the spots flagged in 
GenePix due to bad morphology or suchlike and the spots that were too small to give a 
reasonable measurement were removed from the data set. The reporter filters used removed 
any control spots and empty spots that should not form a part of the final data set, and the 
normalization method used in the final step was a pin-based Lowess normalization. 
 
Measurement to use:  
Mean foreground – Median background. 
 
Spot filter:  
[Raw] Flags ≥ 0 
[Raw] Spot diameter ≥ 60 
 
Reporter filter: 
Gene name not in %YF% 
Gene name not in %SP% 
Gene name not in Neg-HS 
Gene name not in Cy3-Cy5-landmark 
Gene name not in empty 
Gene name not in SC% 
Gene name not in Ctrl% 
 
Normalization:  
Lowess
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3. Results
As described in section 1.4, the main goal of this work was to generate a new model system 
for the analysis of c-Myb function, with a secondary goal of utilizing this new model system 
in preliminary microarray experiments for the determination of potential target genes of this 
hematopoietic transcription factor and its viral counterpart v-MybAMV. The work was divided 
into three sequential main parts, as follows: 
- Construction and verification of plasmids for the Tet-systems (chapter 3.1). 
- Generation and verification of double-stable cell lines with inducible expression of 
three different versions of c-Myb (chapter 3.2). 
- Microarray analysis of the double-stable cell lines (chapter 3.3).  
 
 
Figure 1 Overview of the three c-Myb proteins encoded by the pTRE2hyg constructs. Viral parts of the v-
MybAMV protein (gag and env) are colored purple, viral mutations relative to the sequence of chicken c-Myb are 
indicated by black stars. DBD=DNA binding domain; TAD=Transactivation domain; NRD=Negative regulatory 
domain; R1, R2, R3=Myb repeat 1, 2, 3; FAETL/LZ=Leucine zipper region; TPCR=Threonine/proline rich 
domain or conserved region; EVES=Motif within the NRD; HA=HA-tag. 
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3.1 Construction and verification of plasmids for Dox-regulated expression 
of c-Myb 
As described in section 2.3.1, the basis of the Tet-On and Tet-Off gene regulation systems are 
the integration of two plasmids into the chromosomal DNA of a cell, one plasmid expressing 
the Dox-regulated transactivator rtTA or tTA, respectively, and a response plasmid 
(pTRE2hyg-geneX) encoding the gene of interest under the control of a TRE, and generating 
a new cell line from this double-stable clone. The cell lines used in this work already had the 
regulator plasmids integrated in their genome, thus simplifying the process from a two-step to 
a one-step transformation and selection procedure. The first step in the process of generating 
our double-stable cell lines was to subclone the gene of interest into the MCS of the 
pTRE2hyg vector. 
 
Rather than simply studying the effect of full-length c-Myb, we also wanted to explore the 
changes in gene expression following induced expression of two other versions of c-Myb: A 
truncated version lacking the NRD and v-MybAMV. Experiments performed with these two 
particular Myb proteins might contribute with information on the changes in gene regulation 
that occur during oncogenic activation of c-Myb. Therefore, three different pTRE2hyg 
constructs were made (figure 1): 
- pTRE2hyg-AMV-HA, encoding the viral version of chicken c-Myb, v-MybAMV, with a 
C-terminal HA-tag. 
- pTRE2hyg-hcM[1-443]-HA, encoding a C-terminally truncated version of human c-Myb 
(the N-terminal 443 amino acid residues) with a C-terminal HA-tag (c-Myb1-443). 
- pTRE2hyg-hcM-HA, encoding full-length human c-Myb with a C-terminal HA-tag. 
Construction and verification of each plasmid are described below. All plasmid maps, 
sequences of the primers used as well as the amino acid sequence for human c-Myb can be 
found in the appendix. 
 
pTRE2hyg-AMV-HA 
The plasmid pCIneo-AMV-HA was digested with the restriction enzymes NheI and NotI, and 
the resulting fragment encoding v-MybAMV was then subcloned into the corresponding 
restriction enzyme sites of the pTRE2hyg-vector, as described in figure 2 A. The resulting 
plasmid pTRE2hyg-AMV-HA was verified by restriction enzyme analysis with NheI and 
NotI. The construction and verification of this plasmid was done by post.doc. Vilborg Matre. 
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pTRE2hyg-hcM-HA 
The plasmid pCIneo-hcM-HA was digested with the restriction enzymes SalI and NheI, and 
the fragment encoding c-Myb was then subcloned into the pTRE2hyg vector by digesting this 
vector with the same restriction enzymes before ligating the fragments, resulting in the 7.3 kb 
plasmid pTRE2hyg-hcM-HA, as shown in figure 2 B. The SalI and NheI restriction enzyme 
recognition sites in pTRE2hyg are separated by only 25 bp, therefore the digestion of this 
vector with these restriction enzymes had to be performed in two steps. First the vector was 
digested with SalI, and an aliquot of the mixture was taken for agarose gel analysis to ensure 
proper digestion of the vector. Then NheI was added, and the reaction was left overnight. The 
plasmid was verified by restriction enzyme analysis with SalI+NheI, KpnI, and XhoI.  
 
 
Figure 2 Construction of the plasmids pTRE2hyg-AMV-HA and pTRE2hyg-hcM-HA. A) Subcloning of the 
fragment encoding v-MybAMV from the pCIneo-AMV-HA plasmid into the pTRE2hyg vector.  B) Subcloning of 
the fragment encoding c-Myb from the pCIneo-hcM-HA plasmid into the pTRE2hyg vector. 
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Figure 3 Construction of the plasmids pCIneo-hcM[1-443]-HA and pTRE2hyg-hcM[1-443]-HA. Green and red 
arrows represent the forward and reverse primers C158 and C177, respectively. Blue areas represent sequences 
from the PCR product, dark gray areas sequences from pCIneo-hcM-HA. The PCR product was digested with 
EcoRI and ligated into the corresponding sites of pCIneo-hcM-HA, resulting in a plasmid encoding a C-
terminally truncated version of human c-Myb, c-Myb1-443. The fragment encoding this transcription factor 
(hcM[1-443]-HA) was then subcloned into the pTRE2hyg vector, resulting in the plasmid pTRE2hyg-hcM[1-
443]-HA. 
 
pCIneo-hcM[1-443]-HA and pTRE2hyg-hcM[1-443]-HA 
The plasmid pCIneo-hcM-HA encodes a full length version of human c-Myb with a C-
terminal HA-tag. In order to create a truncated version of this gene, encoding only the first 
443 amino acid residues of the protein with a C-terminal HA-tag, PCR was used, with 
pCIneo-hcM-HA as template (section 2.2.2). The forward primer (C158) was one 
complementary to the sequence just upstream of the MCS of the pCIneo vector, while the 
reverse primer (C177) was designed specifically to create a PCR product terminating 197 
codons of the c-myb sequence that are lacking in AMV v-myb. By digestion of the pCIneo-
hcM-HA plasmid with EcoRI+SalI and replacement of the fragment with the EcoRI digested 
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PCR product, the reading frame would be maintained, yielding a plasmid encoding the N-
terminal 443 amino acid residues of human c-Myb, plus three amino acid residues, an SGSG 
linker and a C-terminal HA-tag (figure 3). This plasmid, named pCIneo-hcM[1-443]-HA, was 
verified with restriction enzyme digestion with XhoI+SalI and NheI+SalI, then sent to be 
DNA sequenced to reveal any potential PCR-generated mutations.  
 
While awaiting the results of the DNA sequencing of pCIneo-hcM[1-443]-HA, pTRE2hyg-
hcM[1-443]-HA was constructed (figure 3). Both pTRE2hyg and pCIneo-hcM[1-443]-HA 
were digested with NheI+SalI, and the pCIneo-hcM[1-443]-HA fragment encoding c-Myb1-443 
was subcloned into the pTRE2hyg vector as had been done in the construction of pTRE2hyg-
hcM-HA from pCIneo-hcM-HA. The plasmid was verified with restriction enzyme digestion 
with EcoRI, then sent to DNA sequencing, as the results from the sequencing of pCIneo-
hcM[1-443]-HA had not been sufficient.  
 
A BLAST search following the sequencing of the plasmids revealed three deviations from the 
sequence of human MYB (numbering from ATG): 
9: A/G: Silent mutation already known, caused by the use of a forward primer for 
chicken c-myb in the construction of the plasmid pCIneo-hcM-FLK, which had been used for 
the construction of pCIneo-hcM-HA.  
39: C/G: Aspartate to glutamate. This mutation was not within the sequence that was 
replaced by the PCR product, and must therefore have originated from the template sequence. 
Some time after the work on this thesis was finished several other c-Myb-encoding plasmids 
used by the research group were sequenced, revealing that this mutation was indeed found in 
all of them. It may well be a polymorphism.  
1039: A/T: Serine to cysteine. Highly likely a PCR generated mutation, and under 
normal circumstances this would have been reason to construct the plasmid anew. However, it 
was judged to be a conservative mutation in a region without any important functional 
domains, and considering the restricted time limits of this work it was decided to go ahead 
with the plasmids regardless of this mutation.  
 
Summary 
The three pTRE2hyg plasmids for the generation of stable cell lines with inducible expression 
of c-Myb had been constructed as according to plan, one for each of the proteins v-MybAMV, 
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c-Myb1-443 and full length human c-Myb. A PCR-generated mutation in pTRE2hyg-hcM[1-
443]-HA had occurred, but was considered to be of minor importance.  
 
 
3.2 Generation and verification of HEK293 cell lines with inducible 
expression of c-Myb 
The cell line used for the generation of stable transfectants with inducible expression of c-
Myb had to be one that did not have any endogenous expression of this transcription factor. 
The choice fell on the HEK293 cell line, a cell line derived from human embryonic kidney 
fibroblasts. The decision was made to try out both Tet-systems, as we had both HEK293 Tet-
On and Tet-Off cell lines available in our lab. The Tet-Off cell line had been tried out 
previously, without much success, whilst the Tet-On cell line was a new investment. 
Comparing these two systems in this manner would also help to determine which one should 
be used for later projects in the group. In total, six different cell lines were to be generated: 
Tet-Off and Tet-On cell lines expressing the proteins v-MybAMV, c-Myb1-443 and c-Myb, 
respectively. The generation and verification of these cell lines are described in the following 
chapter.  
 
3.2.1 Kill-curves – Determination of selective concentration of hygromycin for the 
cell lines HEK293 Tet-On and Tet-Off 
Transfected mammalian cells generally rid themselves of the plasmids in a few days time, but 
a small fraction of the cells integrate the plasmids into their own chromosomal DNA, they 
become stably transfected. Some plasmids harbor an antibiotic resistance marker gene to 
allow for the selection of these few stably tranfected cells. In the case of the pTRE2hyg 
plasmids, the antibiotic resistance gene encodes Hygromycin B phosphotransferase, a kinase 
that inactivates the antibiotic hygromycin. Growing transfected cells in the presence of 
hygromycin will therefore kill all the cells that are not harboring the pTRE2hyg construct, 
whereas the stably transfected cells will survive, and form separate colonies. Diverse cell lines 
have a variable level of tolerance for different antibiotics, so the ideal selective concentration 
of hygromycin had to be determined for the HEK293 Tet-On and Tet-Off cell lines.   
 
 
46 
 
 
 
Chapter 3  Results 
The ideal selective concentration of the antibiotic is that which causes massive cell death 
within five days, and kills all the cells within fourteen days. In order to determine this ideal 
concentration, cells were seeded out in 6-well cell culture plates, and hygromycin was added 
to the medium to a final concentration of 0, 25, 50, 75, 100 or 150 µg/ml. The experiment was 
performed twice, both times the ideal concentration of hygromycin was found to be 100 
µg/ml (results not shown). This concentration was therefore used in the following selection of 
stably transfected clones of the HEK293 Tet-On/Tet-Off cell lines.  
 
 
Figure 4 Transient transfection of HEK293 Tet-Off cells. Western blot shows lysates for cells with or without 
16 hours induction following transient transfection of the cells with the plasmids pTRE2hyg-AMV-HA, 
pTRE2hyg-hcM[1-443]-HA and pTRE2hyg-hcM-HA. 
 
3.2.2 Transfection of 293 Tet-On and Tet-Off cells and clonal selection 
Prior to the generation of stable transfectants, a few tests were performed with transient 
transfections to ensure that every part of the system was working as expected. First, the 
transfection method had to be optimized for the cell line. HEK293 cells are easy to transfect, 
but bind very loosely to the growth surface, a trait that makes gentle handling and very few 
medium changes important for a successful transfection. The Lipofectamine reagent was used 
for these transfections, with a procedure in accordance with the recommendations of the 
supplier, as described in section 2.2.6 (35 mm wells). Western blots of the lysates of 
transfected Tet-Off cells with and without addition of Dox to the medium showed that the 
transfection had indeed worked satisfactorily and the plasmids expressed c-Myb proteins of 
the expected size after induction (figure 4), thus indicating that both the Tet-systems and the 
pTRE2hyg-constructs appeared to be in order. Real-time RT-PCR (section 2.5.4) of Tet-Off 
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cells transfected with pTRE2hyg-AMV-HA indicated a four-to-five fold increase in 
expression of v-MybAMV upon removal of Dox (results not shown), perhaps somewhat lower 
than expected, but according to the Tet system manual, transient transfections generally result 
in far lower expression levels than can be achieved with stable transfections, so it was not a 
great cause for concern. As the transfection method, plasmids and cell lines seemed to be all 
in order, the stable transfectants could be generated.  
 
 
Figure 5 Overview of the selection process for the generation of stable transfectants.  
 
Fresh cultures of Tet-On and Tet-Off cells were seeded out and transfected with the 
pTRE2hyg-constructs as described in section 2.3.4, then split, seeded out in new plates, and 
allowed to form separate colonies while growing in selective medium. These colonies were 
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then transferred to separate wells in a 24 well plate, as described in section 2.3.6 and 
summarized in figure 5. The number of clones originally picked and surviving each selection 
step are summarized in table 4 for each cell line/construct. The reason for the lower number of 
Tet-Off clones isolated and transferred to 24-well plates was simply that there were not that 
many healthy, separate clones available on the plates. 
 
Cell line and construct 24 well plate 6 well plate 10 cm plate Frozen down 
Tet-On v-MybAMV 24 24 24 22 
Tet-On c-Myb1-443 24 24 24 23 
Tet-On c-Myb 24 24 22 21 
Tet-Off v-MybAMV 18 18 18 18 
Tet-Off c-Myb1-443 12 12 12 10 
Tet-Off c-Myb 16 16 15 13 
Total  118 118 115 107 
Table 4 Tet-On and Tet-Off clonal selection. The table shows the number of clones that were isolated and 
survived each selection step from the first transfer of the clones to the 24 well plates until they were finally 
frozen down after they had grown to near confluence in the 10 cm plates. 
 
The process took about two months from the time of transfection until the last clones were 
frozen down, with large clone to clone variations observed. While all clones were transferred 
from the 24- to the 6-well plates after five days, the time it took them to reach near confluence 
before transfer to 10 cm plates varied from four to 22 days. For the majority of the Tet-On 
clones, the time needed was four to seven days, with a few requiring 10-12 days. However, 
the Tet-Off clones generally needed 7-14 days growth, a few clones even a week more than 
that. The Tet-Off cells were also more prone to let go of the growth surface, tended to form 
big lumps of cells rather than grow in the typical monolayer expected of HEK293 cells, and 
were generally smaller than the Tet-On cells. Therefore, the number of cells needed for a 
confluent layer was generally greater for the Tet-Off than the Tet-On cells, perhaps explaining 
some of the added growth time needed.  
 
As a total, 107 clones were frozen down, two cryotubes per clone. Unfortunately, there was 
not enough free space in the N2 tank for all these cells, so they were stored at -80 °C. For a 
short period of storage, this does not pose a great problem, but the storage period for these 
cells became much longer than originally expected.  
 
With the clones selected and isolated, they were ready to be tested for expression of the genes 
encoding c-Myb, c-Myb1-443 or v-MybAMV now integrated in their chromosomal DNA under 
the control of a TRE.  
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3.2.3 Expression of c-Myb in isolated clones 
Depending on the integration site of the plasmid, stably transfected clones display very 
different levels of gene expression upon Dox-regulated induction. Clones with the plasmid 
integrated in areas of the genome with low transcriptional activity will not show proper 
induction of the gene encoded by the plasmid, whereas clones with the plasmid integrated in 
areas of high transcriptional activity (for example close to enhancers) might have such high 
expression that the regulator protein will not be able to quench it in the un-induced state, thus 
making the promoter leak. The ideal clone will be one that exhibits high expression of the 
integrated gene in the induced state, but no expression in the un-induced state. To select the 
clones with these traits Western blots were used to analyze the induction of the c-Myb genes 
in the isolated clones. Several other methods could have been used for this purpose, including 
northern blots and real-time RT PCR that display the level of induction at the mRNA level. 
Western was chosen mainly because this method shows the protein level of induction, which 
is more relevant in most cases, in addition to the possibility of revealing any erroneous protein 
products due to truncations or suchlike.  
 
The different clones were thawed and resuspended in growth medium in batches of six, with 
the total number of cell cultures in use at one time kept at a maximum of eighteen, usually 
twelve. Upon the first passage, new aliquots were frozen down, two cryotubes per clone. In 
total, 54 Tet-On clones were tested, 18 of each of the v-MybAMV, c-Myb1-443 and c-Myb 
clones, as well as 12 Tet-Off clones, six of v-MybAMV, six of c-Myb1-443. For the Western 
blots, 7.5x105 cells were seeded out in six-well plates, two wells per clone, one well with 1 
µg/ml Dox, one well without added Dox. After 16 hours the cells were harvested as described 
in section 2.4.1, the protein concentration of the lysates determined by the MicroBCA method 
(section 2.4.2), and a volume of cell lysate corresponding to 30 µg of protein was used for 
SDS PAGE (section 2.4.3). A standard gel had 13 wells, allowing the analysis of six clones, 
as one well was used for the protein standard, leaving 12 wells for cell lysates. The Western 
blots were performed as described in section 2.4.4, with the primary antibody 5e11 at a 
dilution of 1:200 and the secondary antibody HRP conjugated α-mouse IgG at 1:5000. Figure 
6 shows two typical blots of the Tet-On clones with expression of c-Myb1-443 and c-Myb, with 
clones showing unwanted leaking, low expression or truncated protein products, in addition to 
clones that had the desired qualities. B-Myb is also visible in these blots, as the 5e11 antibody 
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used is specific for the DBD region of all three Myb-proteins c-Myb, A-Myb and B-Myb 
[161]. 
 
 
Figure 6 Western blot of selected Tet-On clones. Tet-On c-Myb-A4 and 443-A2 show a high level of 
background expression, c-Myb-B3 and v-MybAMV-D6 are examples of clones with low induction levels, c-Myb-
C6 and c-Myb1.443-D5 are examples of clones that express proteins of the wrong size (double bands, the upper 
band is c-Myb1-443). The clones c-Myb-D2, c-Myb1-443-B5, c-Myb1-443-D3, v-MybAMV-A4 and v-MybAMV-C4 
were the ones with the desired qualities of low background and high expression upon induction (marked with *). 
 
Of the 54 Tet-On clones tested two had failed to survive the freezing, 22 lacked expression, 9 
had protein products of the wrong size (mainly truncations), and 13 had high background 
expression (leaking promoters). The remaining eight clones were considered to show 
sufficient qualities as to be used for further experiments, based on the criteria of low 
expression of the inserted genes in the uninduced state, and high expression after 16 hours 
induction. One clone was prioritized for each construct, whilst the other potential clones were 
kept as back-up should there be problems occurring with the first clone, or if it was decided to 
compare different clones in later experiments. The selected clones were as follows (figure 6): 
• v-MybAMV-A4: Displayed the desired qualities of high expression upon induction and 
minimal signs of leakage. v-MybAMV-D6 had a somewhat low level of expression and 
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v-MybAMV-C4 revealed some signs of leakage, but both were kept as potential 
alternatives.  
• c-Myb1-443-D3: As v-MybAMV-A4, a very good candidate. c-Myb1-443-B5 was very 
nearly equally qualified, but c-Myb1-443-D3 was prioritized because it had used a 
shorter time on the selection process.  
• c-Myb-D2: Appeared to be the best of the c-Myb clones. Two other clones were kept 
as alternatives; c-Myb-B3, that exhibited rather lower expression upon induction than 
that observed with c-Myb-D2, and c-Myb-B1 (not shown), a clone that showed good 
expression upon induction, but also had some degree of leakage in the uninduced state.  
 
 
Figure 7 Western blot of selected c-Myb1-443 Tet-Off clones. c-Myb1-443-D1 shows a very high background 
expression, the other clones very low induction levels. 
 
Of the Tet-Off clones, only 12 were tested, the reason being the rather poor results observed 
for these 12. Five of the clones had not even survived the freezing process, leaving only seven 
remaining clones to be analyzed by Western. Three of these seven clones revealed complete 
lack of expression of c-Myb, the remaining four clones had such high levels of leakage that 
there was hardly any change to be observed between the samples with or without induction 
(figure 7). Remnants of Dox in the medium might have helped explain some of these results, 
but this should have been avoided by the precautions that had been taken. The cells were 
given an additional medium change four hours after the first to remove any Dox that could 
have been attached to the extracellular matrix of the cells [162], and the FBS used for all these 
experiments was of the Tet system approved version, guaranteed to be free of any tetracycline 
derivatives. These results for the tested Tet-Off clones, in combination with the high mortality 
and odd morphology observed for this cell line alongside the more cumbersome form of 
induction compared to that of the Tet-On system made us decide to put aside the Tet-Off 
clones, and proceed only with the selected Tet-On clones, where we had found potential 
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clones for all three c-Myb constructs, providing cell lines with inducible expression of v-
MybAMV, c-Myb1-443 and c-Myb.  
 
3.2.4 Characterization of the established cell lines; Induction curves 
The Western blots with the 16 hour induction used in the clonal selection described in the 
previous chapter clearly indicated that this induction time was sufficient for generating rather 
high expression levels of the integrated c-myb genes. However, it would be valuable for future 
experiments to analyze how the induction level of the cells changes over time, so as to 
determine proper induction times needed for each experiment. For instance in the case of 
microarray experiments, it would be preferable with as short an induction time as possible, so 
as to determine primary rather than secondary target genes, yet the expression level would 
have to be sufficiently high so as to activate these target genes. An ideal induction time would 
then be one that was long enough to give a sufficiently high expression level of c-Myb to 
activate primary target genes, but still short enough to avoid activation of secondary target 
genes.  
 
 
Figure 8 Western blot of lysates from the Tet-On clones c-Myb-B3 and Tet-On c-Myb-D2 with 0, 4, 8, 16 and 
24 hours induction.  
 
To determine how the level of c-Myb in the cells was altered as a result of the time passed 
after addition of Dox to the growth medium, Western blots were run on lysates from clones 
with 0, 4, 8, 16 and 24 hours induction. Results for two of the selected Tet-On c-Myb clones, 
c-Myb-B3 and c-Myb-D2, are shown in figure 8. This blot clearly illustrates the difference in 
expression levels between the two clones. The expression level in c-Myb-B3 was so low that 
it was a serious cause for concern regarding the usefulness of this clone, thereby confirming 
our choice of c-Myb-D2 as our primary c-Myb candidate for further experiments. c-Myb-D2 
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displays increasing protein levels of c-Myb at all time points, whereas c-Myb-B3 does not 
show any significant increase between the 16 and 24 hour time points.  
 
Based on these blots, it was determined that a four hour induction probably would be 
insufficient for such purposes as microarray analysis, as the level of c-Myb expression would 
be too low at this point, whereas the eight hour induction, at least for the stronger clones such 
as c-Myb-D2, did appear to produce enough c-Myb protein to potentially activate target 
genes. The shortest induction time to be used for those experiments was therefore determined 
to be eight hours. 
 
3.2.5 c-Myb activity in selected clones 
While the Western blots described in the previous sections determined that the clones did 
indeed express c-Myb proteins of the expected size upon induction, they did not reveal 
anything about the activity of these transcription factors. However, luciferase assays with a c-
Myb-responsive promoter construct could be used for this purpose (section 2.4.6). Should the 
clones following induction of c-Myb expression give an increase in luciferase activity, it 
would indicate that the clones expressed active c-Myb proteins that would also be able to 
regulate the expression of endogenous target genes. Should they be unable to activate 
luciferase activity, the reason for this had to be determined to assess whether the problem was 
caused by the clone in question, the cell line or the pTRE2hyg plasmid used for the generation 
of the clones.  
 
There are several different luciferase reporter constructs that can be used for determining the 
activity of c-Myb proteins, based on both synthetic c-Myb-responsive promoters and 
promoters of known c-Myb target genes. A reporter construct from the first category was first 
tried out, one based on the promoter of the c-Myb target gene TRHR [125]. In previous 
experiments performed in our lab using other cell lines than HEK293 (mainly CV-1), this 
reporter construct had given very good results in luciferase assays, but that was not the case 
with the Tet-On clones. The luciferase activity remained virtually unaltered upon induction of 
c-Myb expression for the v-MybAMV-A4, c-Myb1-443-D3 and c-Myb-D2 clones, keeping at the 
same level as that observed for the Tet-On parental cell line. The fact that all three clones had 
failed to increase luciferase activity following addition of Dox indicated that the separate 
clones were unlikely to be at fault, or the pTRE2hyg constructs. To rule out the possibility 
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that the induction had failed the lysates from the luciferase assay were analyzed by Western 
blotting. The blot showed induction levels quite similar to that normally observed for the 
clones in previous experiments, indicating that this was probably not the cause for the lack of 
luciferase activity (results not shown).  
 
 
Figure 9 Luciferase assay for the determination of Myb activity in selected Tet-On clones. The cells were 
transfected with 1 µg  3xGG reporter plasmid, three parallels of each sample. The average luciferase readouts for 
the uninduced cells were set to 1 for each clone/cell line. RLU = relative luciferase units.  
 
c-Myb is not a very strong activator, and requires the assistance of cofactors for the activation 
of several of its target genes. It might be that the reason for the failure to induce expression of 
luciferase when using the TRHR reporter construct in the HEK293 Tet-On cells was simply 
that these cells did not express the cofactors necessary to activate this reporter. It was 
therefore decided to test a different reporter construct: pGL2tk-3xGG. The 3xGG reporter is a 
synthetic Myb responsive promoter, with three repeats of a MRE [163]. With this reporter 
construct as a replacement for the TRHR reporter construct, the luciferase assays were 
repeated for the Tet-On clones v-MybAMV-A4, c-Myb1-443-D3 and c-Myb-D2, in addition to 
parental HEK293 cells, three parallels per sample. This experiment provided results that were 
more consistent with the expected values, with a six-fold increase in luciferase activity for v-
MybAMV-A4 and a 2.5 fold increase for c-Myb-D2 (figure 9). However, the results for c-
Myb1-443-D3 were far from what was expected, which would have been an increase in 
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luciferase activity close to that observed for v-MybAMV-A4. There was hardly any increase at 
all in luciferase activity upon addition of Dox to the c-Myb1-443-D3 clone. To rule out the 
possibility that lack of induction was to blame for this, the lysates were analyzed by Western 
blotting. The blot showed no abnormalities in induction level compared to previous blots 
(results not shown), so there had to be a different explanation for the luciferase assay results.  
 
Generation of stable transfectants always bring along the possibility of clonal effects, 
depending on the insertion site of the plasmid. Should that be the cause of the unexpected 
luciferase assay results for c-Myb1-443-D3, then another c-Myb1-443 clone or a colony of 
transiently transfected parental Tet-On cells would still give results as expected in a luciferase 
assay. Should the fault rather lie with the pTRE2hyg-hcM[1-443]-HA construct, then even 
transiently transfected cells would behave as c-Myb1-443-D3. Therefore HEK293 Tet-On cells 
were transiently transfected with the pTRE2hyg-hcM[1-443]-HA and the luciferase assay 
repeated as described in section 2.4.6, three parallels per sample, and 16 hours induction. The 
results did not differ markedly from those observed for c-Myb1-443-D3: There appeared to be 
no difference in luciferase activity between induced and uninduced cells. This would indicate 
that there would be no use in replacing the c-Myb1-443-D3 clone with another c-Myb1-443 
clone, as the problem would be expected to be the same for all these clones. One might think 
that the PCR mutation in the pTRE2hyg-hcM[1-443]-HA could be to blame, but this problem 
had not occurred for anyone in the lab using the pCIneo-hcM[1-443]-HA construct, which 
includes the same mutation. Due to time constraints, the matter was left unresolved. It was 
simply decided to put aside the c-Myb1-443 clones, and go ahead with only the v-MybAMV and 
c-Myb clones.  
  
In the light of these results, it was determined that the v-MybAMV-A4 and c-Myb-D2 clones 
were qualified for use in further experiments, as they both appeared to express active c-Myb 
proteins, whereas all plans for experiments with the c-Myb1-443 clones were put aside due to 
the lack of c-Myb activity in these cells.   
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3.3 Microarray analysis of cell lines with induced expression of c-Myb and 
v-MybAMV 
When the work on this thesis was begun in 2002, the microarray technology was still a rather 
new method, with all the difficulties that usually entails. When the scanner and hybridization 
station that were to be used for the work on this thesis arrived at our lab the autumn of 2002, 
we were under the assumption that microarray analysis was a simple, sturdy method, well 
documented and should have been safe sailing when it came to generating consistent, good 
data sets. It proved to be everything but.  
 
In the course of the time from the beginning of 2003 until late January 2005 several different 
microarray methods were tried and tested: cDNA arrays vs. oligoarrays, direct vs. indirect 
labeling, manual hybridizations vs. automated hybridization stations. As the technology was 
so new, and changed so fast, the recommendations from the NMC and others on how to 
perform microarray experiments kept changing rapidly. While we were still in the process of 
optimizing a procedure, a new procedure that was assumed to be superior to the old one 
became available, and so we altered our method once again rather than try to make the old 
one work. In general, there were not performed a sufficient number of hybridizations on any 
of the procedures that we chose to abandon to present any results here as the statistical data 
are too poor. Instead, only the final microarray results for the Affymetrix and oligoarray 
analyses are presented in this chapter, whilst our and others general experiences with the 
different microarray techniques are discussed in section 4.3.  
 
This chapter describes the RNA isolations and following microarray results for the two stably 
transfected Tet-On clones v-MybAMV-A4 and c-Myb-D2 that were isolated and tested for both 
expression and activity of their respective v-MybAMV and c-Myb proteins in the previous 
sections.  
 
3.3.1 RNA isolation from c-Myb-D2 and v-MybAMV-A4 
Microarray analyses require rather large pools of RNA of very high quality. Though 10 µg of 
total RNA is sufficient for a single labeling reaction with the FairPlay indirect labeling 
method (section 2.6.2), two labeling reactions for a single sample are required for each slide 
to be hybridized, and with the need for dye-swap replicates, the minimum amount of RNA 
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necessary from a single pool of RNA isolations for a sample is 40 µg. Add to the equation 
that it is not unusual for reactions to fail, hybridizations to go wrong and that one should 
always perform several technical replicates in order to strengthen the statistic material, then it 
becomes apparent that the amount of RNA isolated from a single sample/pool of cells should 
preferably be at least 160 µg. In addition the samples need to be completely free of any 
contaminants such as chromosomal DNA and proteins, and it is also crucial that no RNA 
degradation is allowed to take place.  
 
Cells were seeded out in 15 cm plates at a density so as to be 50-80 % confluent upon 
harvesting, four plates for each clone, allowing for two plates without induction, one plate 
with 8 hours induction, and one plate with 24 hours induction. RNA was isolated from the 
cells with the Trizol method (section 2.5.1), then subjected to DNase treatment and 
purification (section 2.5.2). The Bioanalyzer instrument was used to control the RNA quality 
of the samples, to ensure that no degradation had taken place (section 2.5.3). 
Spectrophotometric analysis of the samples was also done to measure both concentration and 
quality of the RNA (section 2.2.7). A typical yield of RNA from a 15 cm plate of cells was 
200-300 µg from the Trizol isolation, with a final yield of 150-200 µg after all purification 
and quantification steps were done. 
 
For the earlier RNA isolations used for the Affymetrix microarray (section 3.3.2), the 
induction level of c-Myb had to be determined from the RNA sample by the use of real-time 
RT-PCR. For all the following RNA isolations, as a precaution, cells were seeded out in six 
well plates and induced in parallel with the cells for the RNA isolations, so that the induction 
level could be assessed with the use of Western blotting. One could also have isolated protein 
from the Trizol lysates, but this isolation method is somewhat more laborious, and in order to 
properly compare the results with those of previous blots, it was preferable to keep to the 
exact same procedure as before. In general, the results for these blots were in keeping with 
those observed for previous blots of v-MybAMV-A4 and c-Myb-D2, indicating that the cell 
lines had not lost expression of the integrated c-Myb genes.  
 
Thus, with the RNA quality, quantity and level of induction of the integrated c-Myb genes all 
found to be satisfactory, the isolated RNA samples were ready to be used for microarray 
analysis. 
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3.3.2 Affymetrix microarray analysis of c-Myb-D2 
Based on the experience from other microarray projects and our own first attempts at using 
this method, we realized that a full in-house microarray analysis would go far beyond the time 
limit of this thesis. It was therefore decided to try out the Affymetrix microarray system for a 
sample of c-Myb-D2 with 24 hour induction versus a sample without induction.  
 
The Human Genome Focus Array used for this experiment represents over 8 500 human 
sequences from the NCBI RefSeq database, with every sequence represented by eleven 
features (probes) on each array. Based on the number of features observed for each 
gene/sequence in the scan following the hybridization with labeled mRNA, each gene was 
determined to be Present or Absent, which indicates whether it was expressed at a sufficient 
level for observation or not. Of the 232 genes found to be Present in both samples and 
increased, decreased, marginally increased or marginally decreased according to Affymetrix 
statistics, only one was found to be up-regulated above the threshold of two-fold change, and 
it was expressed at a rather low level. The gene in question was that for the lectin-like 
oxidized low-density lipoprotein receptor 1 (LOX-1), a receptor found mainly on epithelial 
cells and assumed to be involved in atherosclerosis (reviewed in [164]). It has never been 
coupled to c-Myb in any way, and the results from this one microarray experiment were not 
convincing enough to start doing so, as it was found to be up-regulated just two-fold. The low 
level of expression also makes the readings somewhat more uncertain, indicating that the 
induction of c-Myb expression in these cells had not had any statistically significant effect on 
the total gene expression pattern in the HEK293 cells in this experiment.  
 
The reason for the lack of statistically significant change in gene expression in the HEK293 
cells upon induced expression of c-Myb was first assumed to be that the cells had lost their 
responsiveness to Dox, and no longer expressed c-Myb. According to the user manual for the 
Tet-system, loss of regulation can also be a result of switching off or methylation of the viral 
promoter. To assess whether the cells had indeed ceased to express c-Myb upon addition of 
Dox to the medium, the induction level of c-Myb in the RNA samples used for the Affymetrix 
microarray analysis was determined with the use of real-time RT-PCR. According to those 
results, the expression of c-Myb was about four-fold up-regulated after 24 hours induction 
(results not shown). This was about the same fold induction observed for the HEK293 Tet-Off 
cells transiently transfected with pTRE2hyg-AMV-HA with only 16 hours induction (figure 
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4). According to the supplier stably transfected cells should show significantly higher fold 
induction than transiently transfected cells, so to be on the safe side the passage of the c-Myb-
D2 clone used for this experiment was discarded, and one of the earliest passages (P2) was 
taken into use for the further experiments. As an extra precaution, as mentioned in section 
3.3.1, Western blots of cells seeded out in parallel with the cells for the RNA isolations were 
also performed to ensure that the clones did not show loss of regulation.  
 
The Affymetrix microarray analysis was not considered a success, as the results were almost 
equivalent to no results at all. This was taken as an indication that the level of expression of c-
Myb was too low in the passage of the c-Myb-D2 clone used to induce any significant change 
in the total gene expression of the HEK293 cells. An earlier passage of the c-Myb-D2 clone 
was therefore taken into use for further RNA isolations and following microarray 
experiments, and precautions were taken to ensure that no RNA isolated from clones with loss 
of regulation was used for microarray experiments. The Affymetrix microarray analysis was 
never repeated, mainly due to cost considerations in combination with the weak results.  
 
3.3.3 Oligoarray microarray analysis of v-MybAMV-A4 and c-Myb-D2 
 
Figure 10 Overview of the oligoarray slides hybridized. The ovals symbolize the RNA samples with their 
respective induction times, the colored lines the dye used for labeling (red: Cy5, green: Cy3).   
 
RNA samples from v-MybAMV-A4 and c-Myb-D2 with 0, 8 and 24 hours induction times 
were used for the oligoarray microarray analysis. The samples were labeled with Cy3 or Cy5, 
and were then hybridized to the slides as described in section 2.6.2-2.6.3. Figure 10 gives an 
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overview of the hybridizations performed, with a total of eight slides used. The scanned 
images were first analyzed in GenePix, where a GPR file containing the identity and analysis 
data for each spot was generated and several spots were flagged due to salt streaks, dust 
particles and similar factors that would otherwise cause problems for the data analysis. The 
GPR file was then transferred to BASE, where the data analysis was performed as described 
in section 2.6.4. Table 5 gives an overview of the number of spots and reporters remaining 
after each filtering and normalization step.  
 
BASE filtering  Tet-On v-MybAMV-A4 Tet-On c-Myb-D2 
 Spots Reporters Spots Reporters
Original data set 92928 21463 92928 21463
Spot and reporter filtering 39900 16111 46720 15882
Lowess normalization 37384 15105 40387 14216
Table 5 Overview of the number of spots and reporters remaining after each filtering and normalization step 
performed in BASE for the microarray analysis of the Tet-On cell lines v-MybAMV-A4 and c-Myb-D2. The 
numbers correspond to all four slides hybridized for each cell line.  
 
The resulting MA-plots (ratio plotted against intensity of the spots, in log-values) for each 
dye-swap pair of hybridizations are shown in figure 11 and 12. Genes that were found to be 
up-regulated at least twofold (M≥1) in both parallel assays (dye-swap hybridizations) are 
marked as red dots in the MA plots, genes found to be down-regulated at least two-fold (M≤-
1) in both assays are marked as green dots. The corresponding data for differentially 
expressed genes for the assay sets of v-MybAMV-A4 are found in tables 6-9, for c-Myb-D2 the 
results are listed in table 10.  
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Figure 11 MA plots for v-MybAMV-A4. Genes found to be up-regulated at least twofold in both arrays (M≥1) are 
marked as red dots, genes down-regulated at least twofold in both arrays (M≤-1) in both arrays are marked as 
green dots.  
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Figure 12 MA plots for c-Myb-D2. Genes found to be up-regulated at least twofold in both arrays (M≥1) are 
marked as red dots. No genes were found to be down-regulated at least two-fold in both arrays. 
 
         
 
Gene name Gene symbol M (2) A (2) M (1) A (1) M of 8h A of 8h 
GA binding protein transcription factor, alpha subunit 60kDa GABPA -1.56 1.65 -1.02 2.41 -1.29 2.03 
Nuclear transcription factor Y, alpha NFYA -1.04 1.30 -1.05 2.10 -1.05 1.70 
Benzodiazepine receptor (peripheral) BZRP -1.06 1.47 -1.00 2.33 -1.03 1.90 
Dystrophia myotonica-protein kinase DMPK -1.99 1.48 -2.64 1.92 -2.31 1.70 
RAB11 family interacting protein 4 (class II) RAB11FIP4 -1.12 1.80 -1.16 2.31 -1.14 2.06 
Mature T-cell proliferation 1 MTCP1 -1.26 1.60 -2.78 1.94 -2.02 1.77 
PREDICTED: similar to RIKEN cDNA 9530066K23 [Source:RefSeq_peptide_predicted;Acc:XP_371777]  -1.61 1.10 -1.11 2.37 -1.36 1.73 
Ribosomal protein L28 RPL28 -1.56 1.57 -2.59 2.19 -2.07 1.88 
Mitochondrial tumor suppressor 1 MTUS1 -1.04 1.78 -3.22 2.14 -2.13 1.96 
Nucleosome assembly protein 1-like 5 NAP1L5 -1.02 1.12 -2.52 2.11 -1.77 1.62 
Tripartite motif-containing 62 TRIM62 -1.01 1.64 -1.46 2.20 -1.24 1.92 
WIRE protein WIRE -1.04 1.67 -1.66 2.22 -1.35 1.95 
KIAA1463 protein KIAA1463 -1.38 1.96 -1.20 1.55 -1.29 1.75 
B-cell CLL/lymphoma 6, member B (zinc finger protein) - -1.54 2.34 -1.02 2.44 -1.28 2.39 
Zinc finger protein 692 FLJ20531 -1.21 1.77 -1.02 2.09 -1.11 1.93 
Mitogen-activated protein kinase kinase kinase 7 interacting protein 1 MAP3K7IP1 -1.05 1.97 -2.20 1.28 -1.63 1.62 
Chromosome 14 open reading frame 126 C14orf126 -1.40 1.76 -1.21 2.17 -1.31 1.97 
Adenosine A2b receptor ADORA2B -3.01 0.90 -1.10 2.15 -2.05 1.52 
Cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila) CELSR2 -1.03 1.82 -1.58 2.09 -1.30 1.95 
Pygopus homolog 2 (Drosophila) PYGO2 -1.11 1.39 -1.07 2.15 -1.09 1.77 
Mediator of RNA polymerase II transcription, subunit 28 homolog (yeast) MED28 -1.86 1.12 -1.21 1.97 -1.54 1.55 
Homo sapiens cDNA FLJ12364 fis, clone MAMMA1002384 N/A -1.27 2.04 -1.24 1.86 -1.26 1.95 
V-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 -1.24 0.93 -1.27 2.19 -1.25 1.56 
HEJ1, [Source:Uniprot/SPTREMBL;Acc:Q96RF1]  -1.33 2.35 -1.02 2.15 -1.18 2.25 
Kelch-like 24 (Drosophila) DRE1 -2.00 1.36 -1.79 2.26 -1.90 1.81 
FKSG39 (FKSG39)  -2.17 1.56 -1.29 1.99 -1.73 1.78 
Table 6 Genes found to be down-regulated at least two-fold in both microarray hybridizations of the RNA isolated from the v-MybAMV-A4 cell line after 8 hours induction. 
Numbering in brackets next to the M and A values correspond to the slide number from figure 11.  
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Gene name Gene symbol M (2) A (2) M (1) A (1) M of 8h A of 8h 
Heterogeneous nuclear ribonucleoprotein L HNRPL 1.13 1.91 1.28 2.32 1.21 2.12 
Mannose-P-dolichol utilization defect 1 MPDU1 1.27 2.03 1.25 2.15 1.26 2.09 
Kruppel-like factor 11 KLF11 2.12 0.69 2.02 3.03 2.07 1.86 
Zinc finger, MYND-type containing 15 ZMYND15 3.88 1.57 1.22 2.25 2.55 1.91 
cancer susceptibility candidate 2 - 1.61 1.61 1.56 2.26 1.59 1.93 
Hypothetical protein BC009732 LOC133308 1.84 1.68 1.87 1.93 1.85 1.81 
Immunoglobulin lambda chain, mAb 667 Igk-V8 2.16 1.09 1.70 2.05 1.93 1.57 
Diacylglycerol kinase, delta 130kDa DGKD 3.06 1.63 1.27 2.34 2.16 1.99 
EGF-like repeats and discoidin I-like domains 3 EDIL3 2.35 1.89 1.67 2.30 2.01 2.09 
Obscurin-like 1 KIAA0657 2.11 1.67 1.54 2.17 1.82 1.92 
Cullin-associated and neddylation-dissociated 1 TIP120A 1.69 1.69 1.35 2.32 1.52 2.00 
KIAA1211 protein KIAA1211 4.02 1.60 1.35 2.26 2.69 1.93 
Tripartite motif-containing 43 TRIM43 3.31 0.78 1.03 1.93 2.17 1.36 
MRNA; cDNA DKFZp434L1016 (from clone DKFZp434L1016)  9.15 0.94 1.05 2.22 5.10 1.58 
Chromatin modifying protein 4A C14orf123 2.66 1.60 1.24 2.31 1.95 1.95 
Crystallin, zeta (quinone reductase)-like 1 CRYZL1 1.26 1.94 1.12 2.44 1.19 2.19 
Glypican 6 GPC6 2.00 1.78 3.45 1.60 2.73 1.69 
Hypothetical protein BC015395 LOC130940 1.19 1.50 2.25 1.74 1.72 1.62 
Similar to hypothetical protein SB153 isoform 1  1.91 0.98 3.27 1.77 2.59 1.37 
Stringency oligo ctrl6-8, Match 80%  4.80 1.14 2.57 2.09 3.69 1.61 
Table 7 Genes found to be up-regulated at least two-fold in both microarray hybridizations of the RNA isolated from the v-MybAMV-A4 cell line after 8 hours induction. 
 
 
 
 
 
 
 
 
 
65 
 
 
 
         
Gene name Gene symbol M (4) A (4) M (3) A (3) M of 24h A of 24h 
Stathmin-like 4 STMN4 -3.53 1.44 -1.93 2.64 -2.73 2.04 
Trans-golgi network protein 2 TGOLN2 -2.98 1.22 -1.54 1.91 -2.26 1.56 
Family with sequence similarity 89, member B MTVR1 -1.47 1.99 -1.13 1.77 -1.30 1.88 
BM88 antigen BM88 -1.39 1.99 -1.67 2.81 -1.53 2.40 
Zinc finger homeobox 1b ZFHX1B -3.29 1.40 -1.43 2.01 -2.36 1.71 
Chromatin modifying protein 5 SNF7DC2 -4.15 1.76 -1.27 2.51 -2.71 2.13 
Rap guanine nucleotide exchange factor (GEF) 5 RAPGEF5 -1.48 0.80 -2.87 1.13 -2.18 0.97 
Butyrophilin, subfamily 3, member A1 BTN3A1 -1.91 0.74 -1.50 1.06 -1.70 0.90 
Gelsolin (amyloidosis, Finnish type) GSN -1.36 1.93 -1.04 2.22 -1.20 2.07 
Mastermind-like 2 (Drosophila) MAML2 -1.32 1.89 -1.28 2.40 -1.30 2.14 
Protein kinase, AMP-activated, gamma 3 non-catalytic subunit PRKAG3 -2.60 1.51 -1.44 2.52 -2.02 2.02 
Cholinergic receptor, nicotinic, alpha polypeptide 3 CHRNA3 -2.86 1.20 -1.31 2.29 -2.08 1.74 
Eyes absent homolog 1 (Drosophila) EYA1 -1.56 1.68 -1.03 2.23 -1.29 1.95 
Opioid receptor, kappa 1 OPRK1 -3.21 1.26 -1.43 2.28 -2.32 1.77 
Hypothetical protein FLJ22955 FLJ22955 -1.14 1.58 -1.49 2.19 -1.31 1.89 
Hypothetical protein FLJ30990 FLJ30990 -1.75 1.68 -1.20 1.82 -1.47 1.75 
Chromosome 14 open reading frame 145 C14orf145 -1.98 1.59 -1.22 2.32 -1.60 1.96 
Hypothetical LOC339483 LOC339483 -3.29 1.45 -1.54 2.26 -2.41 1.86 
Table 8 Genes found to be down-regulated at least two-fold in both microarray hybridizations of the RNA isolated from the v-MybAMV-A4 cell line after 24 hours induction. 
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Gene name Gene symbol M (4) A (4) M (3) A (3) M of 24h A of 24h 
Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) SRD5A1 2.15 1.33 1.35 1.52 1.75 1.42 
Keratin 9 (epidermolytic palmoplantar keratoderma) KRT9 1.92 2.49 1.06 1.79 1.49 2.14 
Protein kinase D1 PRKD1 4.13 0.65 2.16 1.31 3.14 0.98 
Potassium channel tetramerisation domain containing 2 KCTD2 1.29 1.55 1.82 1.28 1.55 1.41 
Chromobox homolog 4 (Pc class homolog, Drosophila) CBX4 2.28 1.79 1.34 1.74 1.81 1.76 
Neurofascin homolog (chicken) NFASC 1.97 1.30 1.15 1.65 1.56 1.48 
Olfactomedin-like 3 OLFML3 2.30 1.79 6.65 0.72 4.48 1.26 
Leucine proline-enriched proteoglycan (leprecan) 1 LEPRE1 1.05 2.08 1.29 1.75 1.17 1.91 
Steroid 5 alpha-reductase 2-like SRD5A2L 2.73 1.63 2.04 1.33 2.39 1.48 
Reticulon 4 receptor RTN4R 1.36 1.17 1.08 1.56 1.22 1.36 
limkain b1 isoform 2 [Source:RefSeq_peptide;Acc:NP_061954]  1.24 2.22 5.57 0.88 3.40 1.55 
CDNA: FLJ22382 fis, clone HRC07514  1.32 1.55 1.33 1.67 1.32 1.61 
Musashi homolog 1 (Drosophila) MSI1 2.51 1.68 1.42 2.03 1.97 1.86 
Zinc finger protein 669 FLJ12606 2.18 1.97 1.24 1.84 1.71 1.90 
Zinc finger, AN1-type domain 2B LOC130617 1.16 1.94 1.30 1.97 1.23 1.95 
SATB family member 2 SATB2 2.86 1.22 2.00 1.54 2.43 1.38 
Tripartite motif-containing 45 TRIM45 2.18 1.64 1.88 1.45 2.03 1.54 
PHD finger protein 20 PHF20 1.69 1.26 3.01 1.60 2.35 1.43 
Randomly generated negative control - 4.58 0.72 2.54 1.34 3.56 1.03 
Table 9 Genes found to be up-regulated at least two-fold in both microarray hybridizations of the RNA isolated from the v-MybAMV-A4 cell line after 24 hours induction. 
 
 
Gene name Gene symbol M (6) A (6) M (5) A (5) M of 8h A of 8h 
Bone morphogenetic protein 5 BMP5 1.87 1.54 1.04 1.19 1.45 1.36 
Transient receptor potential cation channel, subfamily M, member 4 TRPM4 1.24 2.05 1.20 1.20 1.22 1.63 
Cysteine/histidine-rich 1 CYHR1 1.02 1.62 1.09 1.37 1.06 1.49 
   
Gene name Gene symbol M (8) A (8) M (7) A (7) M of 24h A of 24h 
KIAA1160 protein KIAA1160 1.10 1.68 1.02 1.38 1.06 1.53 
Table 10 Genes found to be up-regulated at least two-fold in both microarray hybridizations of the RNA isolated from the c-Myb-D2 cell line after 8 and 24 hours induction. 
No genes were found to be down-regulated in accordance to the criteria used.
Chapter 3  Results  
As is evident in the MA plots, there were not many genes that were found to be up- or down-
regulated in the cells in a statistically significant manner. There appears to be several more 
changes in the v-MybAMV data sets than in those for c-Myb, as would be expected, since v-
MybAMV is a stronger transcriptional activator than c-Myb is, but the MA-plots also reveal 
that the noise level is higher for v-MybAMV, making these data more uncertain, especially for 
the genes that show a low intensity/expression level. Still, the criteria by which the up-
regulated and down-regulated genes were measured were rather strict, and several potential 
genes were discarded due to the fact that they were only present in one of the data sets, since 
it would be impossible to discern dye-specific artifacts from true target genes without 
corresponding spot values for both of the dye-swap parallels. Several dye-specific artifacts 
were observed in the data sets, confirming the importance of such dye-swap hybridizations 
and our strict criteria for singling out potential target genes for c-Myb and v-MybAMV.  
 
Gene symbol M(8) A(8) M(7) A (7) M (6) A (6) M (5) A (5)
WT1 - - 1.07 1.38 -0.60 1.33 -0.23 1.98
GBX2 - - - - - - 0.16 1.69
CD34 - - -4.85 1.80 - - -4.94 1.94
CD4 - - - - 1.76 1.82 0.06 1.95
MAT2A 0.05 3.23 -0.15 3.25 -0.08 3.24 -0.03 3.34
TRHR -0.12 2.69 0.03 2.75 0.09 2.73 -0.17 2.87
Table 11 Microarray results for some previously validated c-Myb target genes in the hybridizations performed 
with samples from the Tet-On c-Myb-D2 cell line. M and A represent the log2 ratio and log10 intensity levels 
for the spots on the array, respectively, the numbers in brackets correspond to the slide number, as described in 
figure 10. All M-values are reported as log2 ratio for induced cells over un-induced cells. Notice in particular the 
M-values for CD34, a reporter with typical dye-specific expression pattern. 
 
Also the data for several other known c-Myb target genes, such as WT1, GBX2, CD34, CD4, 
MAT2A and TRHR (see references in table 1) were studied in the c-Myb-D2 data sets (slides 
five to eight), and in those cases where the spots for the gene were present (sufficiently high 
intensity, and not flagged), there was hardly any change in expression levels (table 11). CD34 
appears to be very strongly down-regulated in the data sets for slide five and seven, but there 
is a known problem with this reporter that it always appears to be down-regulated (green) 
(information from the BASE website). It is not present in the data sets for slide six and eight. 
The data presented in table 11 also indicate one of the major problems regarding our selection 
criteria, with the absence of several reporters in the data set from some of the slide 
hybridizations. This is also quite evident from table 5, where the number of spots remaining 
after the filtering process is but a fraction of the spots in the original data set. 
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Possibly we may have found more potential target genes for c-Myb and v-MybAMV had 
several more hybridizations been performed, which would also have strengthened the 
statistical basis, but the time limitations of this thesis did not allow for further experiments. In 
general, the expression of c-Myb and v-MybAMV in the HEK293 cells appeared to have minor 
effects on the gene expression profile of the cells, as had been observed with the Affymetrix 
microarray analysis of c-Myb-D2.  
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4. Discussion 
The main aim of this study was the generation and verification of cell lines with inducible 
expression of the hematopoietic transcription factor c-Myb, its viral counterpart v-MybAMV or 
the C-terminally truncated c-Myb1-443, with the secondary aim of employing these cell lines in 
microarray experiments for the determination of potential target genes for these transcription 
factors. Our hope was that by comparison of the effects each of these transcription factors had 
on the global gene expression patterns of the cells in which they were expressed, we might 
come one step closer to understanding some of the underlying mechanisms for oncogenic 
activation of c-Myb as well as its normal biological function.  
 
The work on this thesis mainly became a matter of establishing new methods for the group, 
both regarding the generation of double-stable cell lines and the microarray experiments. This 
discussion will therefore reflect largely on these experiences, dwelling on technical aspects 
concerning the Tet gene regulation systems and the microarray experiments, in addition to the 
issues regarding the c-Myb1-443 construct and our findings from the preliminary microarray 
experiments performed on the selected cell lines.  
 
 
4.1 Choice of cell line and experiences with the Tet-On and Tet-Off systems 
The main criterion for the parental cell line chosen for the generation of the stable cell lines 
with inducible expression of c-Myb was that it did not display endogenous expression of this 
transcription factor. Further, the cell line should preferentially have adherent growth 
properties to allow for easier selection of stably transfected clones. These criteria excluded 
most hematopoietic cell lines, yet we still wished to use a cell line in which c-Myb would be 
in a cell environment as close to its native one as possible. The choice of Clontech’s Tet-
systems as our gene regulation system in combination with the desire to test out both the Tet-
On and Tet-Off system limited the number of available cell lines further, resulting in the 
choice of the HEK293 Tet-On and Tet-Off cell lines. HEK293 is a well established human 
cell line that appeared to possess all the desired qualities for our purposes, though later 
findings indicated that we might have profited from a different choice of cell line. Howe et al. 
reported as early as in 1995 that the HEK293 cell line generally displayed decreased 
responsiveness in tetracycline regulated gene expression systems compared to GH3 cells 
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[165], findings that were in keeping with our observations that the stably transfected clones 
generally did not exhibit very large changes in expression level of c-Myb upon induction, 
though we did manage to find a few clones that did respond well to Dox. The problem has 
been reported to be of particular significance in the Tet-On system, and Clontech has recently 
marketed a HEK293 cell line with a new version of the Tet-system designed to overcome 
these drawbacks; the Tet-On Advanced Inducible Gene Expression System [166]. This system 
is optimized for transgenic animals in particular, where the previous Tet-On system was 
hampered by varying levels of Dox in different organs, and in certain cell lines where the 
rtTA was unstable, resulting in background expression of the Tet-regulated gene. The main 
difference between the new Tet-On system and the one used in this thesis lies in the new 
rtTA’s increased sensitivity to Dox and its decreased affinity for the TREs in the uninduced 
state. 
 
The odd morphology we observed for the Tet-Off cells in particular is also a known feature of 
HEK293 cells; their morphology often changes following transfection. Clontech has also 
reported that the Tet-On and Tet-Off cells are only semi-adherent, not adherent as the parental 
cell line HEK293 is. This was particularly obvious with the Tet-Off cell line used in this 
work, in which the cells did not maintain the monolayer epithelial growth pattern expected of 
HEK293 cells, but rather formed dense clumps of cells. The cells were also generally smaller 
than those of the Tet-On cell line. This odd morphology, in combination with the high 
mortality rate following storage, was the main reason why we decided not to proceed further 
with the Tet-Off clones. The prolonged non-optimal storage conditions (-80 °C rather than in 
liquid nitrogen vapor) may have been largely to blame for the mortality rate, since HEK293 
are considered to be rather sensitive cells in this regard (information from Clontech website). 
The morphology and mortality issues for the Tet-Off cells thus cemented our preference for 
the Tet-On system, which was also more convenient to use in regard to the induction 
procedure and time intervals for addition of antibiotics to the growth medium, and from which 
we succeeded in our goal of generating double-stable cell lines with inducible expression of c-
Myb or v-MybAMV. 
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4.2 Issues regarding the c-Myb1-443 construct and clones 
The lack of luciferase activity in the reporter assays for the pTRE2hyg-hcM[1-443]-HA 
construct and c-Myb1-443 is a matter that can only be described as baffling. Western blots 
performed indicated that a protein of the expected size was expressed upon induction, and was 
recognized by the 5e11 antibody specific to c-Myb DBD. A Western blot was also performed 
with an α-HA antibody (not shown), indicating that the HA-tag was intact as well, ruling out 
the possibility of frameshift mutations. More importantly, the pCIneo-hcM[1-443]-HA 
construct and constructs derived from it had been used in reporter assays in several other cell 
lines with results as expected, yielding an increase in luciferase activity quite similar to that 
observed for v-MybAMV constructs (Marit Ledsaak and Ole Stian Bockelie, personal 
communication). These results indicate that the PCR-generated mutation in the construct is 
probably not to blame for the lack of activity of c-Myb1-443 in HEK293 cells. A full 
sequencing of the entire construct might be the right action to take to find the reason behind 
these puzzling results, or perform a luciferase assay with the HEK293 Tet-On cells using the 
pCIneo-hcM[1-443]-HA construct in order to determine whether there are cell type specific 
factors at work inactivating c-Myb1-443 specifically, but not c-Myb or v-MybAMV.  
 
 
4.3 Microarray analysis – Technical considerations and challenges 
When the work on this thesis was begun in 2002, microarray technology was truly the method 
of the moment. For a time it almost seemed as if every lab that could possibly afford it were 
purchasing scanners and hybridization equipment, and our lab was one of them. We were at 
the time under the impression that the microarray technology was pretty well established, 
based partly on the optimism still reigning in the majority of the scientific community, but 
mostly on our communication with the NMC, where they had successfully been producing in-
house spotted slides and performing hybridizations for some time. Still, it was about this time 
that critics of the technology and the way in which it was being used voiced their opinions 
loudly enough to be heard. The initial optimism in the second half of the nineties had begun to 
dim somewhat as it became apparent that the microarray technology was not quite the 
straight-forward analysis method for determination of target genes that it was first assumed to 
be. When used correctly it is an immensely powerful tool, but it is also a method that places 
strict demands on experimental design and reproducibility in order to contribute with 
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meaningful results. Statistical considerations have now become a major factor due to the huge 
amounts of data generated. A 99 % confidence interval may seem good in other contexts, but 
when the number of reporters studied is 23 000, this will result in a statistical 230 false 
positives/negatives.  
 
General aspects concerning microarray technology have been extensively reviewed over the 
past five years, and a full discussion of these aspects is beyond the scope of this thesis. Rather 
I would like to point out a few of our personal experiences from the challenging but 
rewarding process of establishing a procedure for microarray analyses in our lab, some of the 
experiences reported from the NMC and their collaborators and draw in a few relevant 
publications. 
 
The first aspect to consider when planning microarray experiments is experimental design. 
What sample should be used as reference, what samples should be hybridized together? What 
is the biological relevance of the comparison, what are the sources of variation? How much 
sample RNA is available, how many hybridizations can be performed, and what are the 
limiting factors? Once these factors have been established, one can begin to consider what 
experimental design to use. In our case we had a quite simple experimental design, as our 
main objective was just to compare gene expression in cells with or without expression of c-
Myb or v-MybAMV. Should we however have wished to study further the differences between 
c-Myb and v-MybAMV expressing cells, we might have benefited from the use of a different 
experimental design, one where there was a common denominator in all the hybridizations. 
Had we used RNA from the parental HEK293 Tet-On cell line rather than the un-induced c-
Myb-D2 and v-MybAMV-A4 clonal cell lines, we would have achieved a better statistical basis 
for direct comparison of these two double-stable clones, but the statistical data for potential 
target genes for each clone would have suffered from increased noise levels due to the larger 
biological differences between reference and sample RNA. As it were, we designed the 
experiments based on our consideration of what was more important of direct comparison of 
c-Myb and v-MybAMV or target genes for each transcription factor, and our choice fell on the 
target genes. General considerations for experimental design are discussed in [167-169]. 
 
The questions regarding experimental design also relate to the discussion concerning technical 
replicates versus biological replicates. A technical replicate will in this regard be two separate 
hybridizations of the same RNA samples, whereas a biological replicate will be two separate 
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hybridizations of RNA samples from two individuals, cell lines or animals. Ideally, one 
should perform both, which was also one of reasons why we kept multiple potential clones for 
each construct in this work. Based on our observations and the reports from the NMC 
regarding reporters such as CD34, technical replicates in general and dye-swap replicates in 
particular are important when performing microarray experiments with in-house spotted 
arrays, as there are a fair number of spots/reporters that are dye-specific and these can only be 
revealed by use of such replicates. In addition there is the element of salt streaks and other 
factors that result in the removal of several reporters from the data set as we observed (table 
5), reporters that may have been quite interesting for the study. However, if one is using 
commercial microarray platforms such as Affymetrix, the technical variation from experiment 
to experiment is reported to be negligible [170] while the cost per hybridization is higher, so 
in this case it would be a better choice to prioritize biological replicates. In either case one 
cannot draw any conclusions based on a single microarray hybridization, so replicates are an 
absolute necessity, but whether they should preferentially be technical or biological replicates 
is highly dependent on the microarray platform used.  
 
In this work we tried out both in-house spotted arrays (cDNA-arrays and oligo-arrays) and the 
Affymetrix platform. The main drawback with the Affymetrix platform is the cost, which is 
many times that of in-house spotted arrays. When one can perform perhaps ten hybridizations 
with in-house spotted arrays for the same price as a single Affymetrix hybridization pair 
(Affymetrix uses one array per sample), it comes down to simple cost considerations for most 
laboratories. The first in-house spotted microarrays we tried out in this work were 15k cDNA 
arrays based on the ResGen 40k I.M.A.G.E clone set. These arrays went out of production at 
the NMC during the course of this work, mainly due to the introduction of the cheaper and 
better 21k oligo-arrays. Reports of uneven hybridizations and some reporters that did not 
represent the correct gene were key factors in the choice made by the NMC to discontinue the 
production of the cDNA arrays. Several articles have presented results from comparisons of 
arrays manufactured with oligos or cDNA fragments, and generally the long oligo-arrays (50-
80 bp) have come out favorably [171, 172], and have now nearly completely taken over for 
the cDNA arrays.  
 
For labeling of the samples to be hybridized to these in-house spotted arrays, we briefly tried 
out a direct labeling method for incorporation of Cy3 and Cy5 before ending up with the 
FairPlay protocol for indirect labeling. The few samples we did manage to hybridize after 
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labeling with the direct method illustrated the main weakness of this method: Our samples 
had high incorporation of Cy3, but hardly any Cy5, assumed to be caused by the difficulties 
experienced by the reverse transcriptase due to the larger size of the Cy5 molecules. Which 
method is superior has been a matter of some debate, as the results are difficult to compare 
directly, since the labeling method appears to have a rather significant effect on the results. It 
has become increasingly clear over the past years that different microarray platforms may 
yield strikingly different results, depending on choice of labeling method, array type and 
hybridization conditions [173, 174]. In addition there is the matter of automated hybridization 
stations versus manual hybridizations. We tested both methods in this work, and the results 
were in keeping with the information presented by the manufacturers of the hybridization 
stations and the experiences of the staff at NMC: Automated hybridization stations result in 
lower background, but also weaker spots. We chose the use of automated hybridization 
stations mainly due to the more homogenous distribution of the hybridization solution, as 
these stations pump the solution back and forth across the slide in the hybridization chamber, 
resulting in lower across-slide variation than observed for the manual hybridizations where 
the solution remains still across the slide as capillary forces hold the cover slide in place.  
 
A few environmental considerations became apparent to us during this work, mainly that 
microarray experiments should not be performed in July or August due to higher ground-
levels of ozone in combination with heat and humidity. The Cy-dyes are very sensitive to 
oxidation and sunlight and the slides to increased humidity, all factors that contribute to 
making the summer months an unfortunate time of year for microarray experiments. Reducing 
the level of ozone in the microarray laboratory is reported to significantly increase the 
reproducibility of microarray experiments where Cy-dyes are used for labeling [175]. 
 
All in all, microarray experiments come down to statistics and minimizing sources of 
variation while keeping in mind the goal of the study and the experimental design. Following 
such a process of methodological trial and error regarding a technology that is constantly 
evolving has been a challenge, but a rewarding one at that. 
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4.4 Microarray results for v-MybAMV and c-Myb 
Due to the time limitations of this thesis, the number of microarray hybridizations we could 
perform became too few to be able to draw any conclusions concerning potential target genes 
for c-Myb or v-MybAMV. We did however make a few interesting observations regarding 
differences in the gene expression profiles of the cells in which these two versions of c-Myb 
were expressed. It would appear that v-MybAMV both represses and activates more genes than 
c-Myb does, not surprising in view of its lack of negative regulation. The noise level of the v-
MybAMV hybridizations is also higher than those for c-Myb, as is evident by the larger spread 
of the spots with low intensity in the v-MybAMV MA plot.  
 
Expression of c-Myb in the HEK293 cell line did not appear to induce differential expression 
of many genes either in the Affymetrix or the oligo-array hybridizations. In addition, the 
KIAA1160 protein reporter found to be the only reporter up-regulated more than two-fold in 
the data set from the 24 hour induction has been reported to probably not represent a gene 
(information from the BASE website). LOX-1 (OLR1) was found to be up-regulated two-fold 
in the Affymetrix experiment, but was not present in the oligo-array data set for c-Myb-D2 24 
hour induction. However, it was present in the 8 hour induction data set, where it was found 
to be up-regulated in the data corresponding to slide six, but did not display any altered 
expression in the data set for slide five (data not shown). It is also interesting to note the 
results for TRHR in the data sets in light of the lack of response observed in the luciferase 
assays with the reporter construct based on the TRHR promoter, indicating that c-Myb is not 
able to activate neither the reporter construct nor resident chromosomal gene of TRHR in 
HEK293 cells. The MA plots show that there are several spots that are up- or down-regulated 
in the data set that have not been found to be statistically significant in accordance to our 
stringent criteria, but altering these criteria would also result in an increase in false positives 
and negatives, making it difficult to discern Cy-dye specific artifacts or noise from true c-Myb 
targets. Performing more hybridizations is probably the best way to determine whether c-Myb 
really is able to significantly alter the expression of potential target genes in HEK293 cells, as 
the present data set is insufficient for this purpose.  
 
For v-MybAMV the microarray experiments resulted in a far longer list of potential candidates 
than for c-Myb, but this list also includes several unknown reporters and some reporters that 
are clearly not potential target genes, such as the randomly generated negative control and the 
 
77 
 
 
 
Chapter 4  Discussion 
stringency oligo found in the data sets in table 7 and 9. There is also a distinct lack of 
correlation between the data sets from the 8 and 24 hours induction samples, as there are no 
genes that are found in both data sets. As for the data sets for the c-Myb samples, these are 
just preliminary results, and repeated experiments may result in quite different lists of 
potential target genes. Still, it is interesting to note the occurrence of genes like MYBL1 (A-
Myb), MTUS1, MTCP1 and GSN, and hopefully further experiments will help to determine 
which, if any, genes on these lists are true v-MybAMV target genes. 
 
During the time course of this thesis, three articles were published where a microarray 
approach had been utilized to study the transcription factors c-Myb, A-Myb, B-Myb and v-
MybAMV [141-143]. These articles highlight several important aspects regarding the Myb 
proteins:  
• There is little correlation between the genes regulated by c-Myb, A-Myb and B-Myb, 
respectively. 
• There is little correlation between the genes regulated by c-Myb and v-MybAMV. 
• There is hardly any correlation between the genes regulated by the respective Myb 
proteins in different cell lines.  
It would appear that the Myb transcription factors function in a context specific manner that is 
highly dependent on the availability of co-activators, cooperating transcription factors and 
proteins mediating post-translational modifications (discussed in [143]). These results also put 
into question the results from previous reporter assays, as it would appear that these are not 
representative for the function of Myb proteins in their native cellular environment. In light of 
these findings, it will be interesting to see if further microarray experiments in our model 
system will display the same results as was observed in these experiments with adenovirus 
transfected cell lines and use of the Affymetrix microarray platform. Our preliminary results 
do indeed indicate that v-MybAMV is not just a more active version of c-Myb, but a 
transcription factor with a unique set of activities, as was observed by Liu et al. [141].  
 
 
4.5 c-Myb – A context-specific and repressed activator of transcription  
In the past few years it has become increasingly evident that c-Myb is a transcription factor 
that is highly dependent on post-translational modifications and interaction partners to fulfill 
its potential as a transcriptional activator. Many of the modifications and interaction partners 
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function to repress c-Myb activity, while others are vital for activation of certain target genes 
(discussed in chapter 1.3). In light of the recent articles on microarray experiments with c-
Myb [141-143], it is quite interesting to note how many of the previously published articles 
regarding c-Myb function have reported conflicting results depending on the model system 
used, as mentioned in the introduction of this thesis and observed in our own experiments 
with the luciferase assays with the TRHR reporter construct, a construct that has worked well 
in other cell lines, but not in HEK293. It is also quite interesting to note the large difference in 
the number of genes found by Liu et al. to be differentially regulated by c-Myb and v-
MybAMV in MCF7 cells compared to primary human monocytes that are more closely related 
to the myeloid cells transformed by v-MybAMV [141]. Based on their results, it would seem as 
if these transcription factors are far more active in a cellular environment that is more akin to 
their native environment than in other human cell lines, and regulate different sets of genes in 
these cells, raising the question of whether c-Myb is mainly present in a repressed form in cell 
lines in which it does not naturally belong. Whether this repressed form is the result of post-
translational modifications and/or interaction partners or lack of these remains an open 
question, and will probably be the subject of many studies to come. 
 
 
4.6 Concluding remarks and future prospects 
The main goal of this thesis was to establish a model system for the study of c-Myb and its 
viral counterpart v-MybAMV as well as a truncated version of c-Myb, designated c-Myb1-443. 
We succeeded in establishing two cell lines with inducible expression of c-Myb or v-MybAMV, 
but the cell lines with inducible expression of c-Myb1-443 were put aside until the reasons 
behind the bewildering observations made during the verification process have been 
determined. These two cell lines, c-Myb-D2 and v-MybAMV-A4, will be a valuable asset for 
the laboratory group in further studies regarding determination of target genes for c-Myb and 
v-MybAMV as well as other studies that may contribute to the understanding of mechanisms 
underlying oncogenic activation of c-Myb.  
 
The preliminary microarray experiments performed in this work will need to be repeated and 
verified with other methods such as ChIP, real-time RT-PCR or Western in order for us to be 
able to draw any conclusions regarding target genes for c-Myb and v-MybAMV, but a few 
interesting observations were made, mainly that c-Myb appears to be a rather weak activator 
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of transcription in the HEK293 cells, whereas v-MybAMV both activates and represses more 
genes than c-Myb. In addition it is interesting to note that several genes reported to be c-Myb 
targets in other model systems are not differentially expressed in this system, findings that are 
in keeping with recent publications that report c-Myb to be a highly context-specific 
transcription factor with differing activities in diverse cell lines. 
 
The context-specific aspects regarding c-Myb may indicate that a more biologically relevant 
model system for the study of this transcription factor would be knock-down of c-Myb in cell 
lines with endogenous expression of c-Myb. Such a model system is already established in 
our lab, based on siRNA knock-down of c-Myb in the K562 cell line. Further experiments 
with both this siRNA/K562 system and the model system established in the work on this 
thesis will hopefully contribute to an increased understanding of the hematopoietic 
transcription factor c-Myb and its biological function.  
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Appendix 
 
Appendix I: Materials and solutions 
 
Commercial kits and solutions 
 
Product Supplier 
Cy3, NHS-ester leaving group Amersham  
Cy5, NHS-ester leaving group Amersham 
ECL Plus kit Amersham 
FairPlayII Microarray Labeling Kit Stratagene 
FuGENE 6 Transfection Reagent Roche 
Genopure Plasmid Maxi Kit Roche 
GFX Micro Plasmid Prep Kit Amersham 
GFX PCR DNA and Gel Band Purification kit Amersham 
Lipofectamine Invitrogen 
Luciferase assay system Promega 
Micro BCA Protein Assay Reagent Kit Pierce 
Passive lysis buffer Promega 
RNA 6000 Nano LabChip kit Agilent Technologies 
RNeasy Mini Kit Qiagen 
SYBR Green Dye Roche 
Trizol reagent Invitrogen 
First strand cDNA synthesis kit for RT-PCR Roche 
FastStart DNA master SYBR green I Roche 
 
 
Antibiotics 
 
Product Supplier 
Ampicillin Sigma 
Doxycyclin Clontech 
Hygromycin B Invitrogen 
Penicillin/streptomycin Invitrogen 
 
 
Antibodies 
 
Antibody Host Supplier/reference 
5e11, α-c-Myb  Mouse  [161] 
α-mouse IgG, HRP conjugated Goat Zymed 
α-HA, polyclonal Rabbit Sigma-Aldrich 
α-rabbit IgG, HRP conjugated Goat Zymed 
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Enzymes 
 
Restriction enzyme Buffer Supplier 
EcoRI NEBuffer EcoRI New England Biolabs 
EcoRV NEBuffer3 + BSA New England Biolabs 
KpnI Buffer KpnI MBI Fermentas 
NheI NEBuffer2 + BSA New England Biolabs 
NotI NEBuffer3 + BSA New England Biolabs 
PshAI NEBuffer4 + BSA New England Biolabs 
SalI NEBuffer3 + BSA New England Biolabs 
XhoI NEBuffer2 + BSA New England Biolabs 
XmnI NEBuffer2 + BSA New England Biolabs 
 
Other enzymes Buffer Supplier 
Vent DNA polymerase  ThermoPol buffer New England Biolabs 
Taq DNA polymerase ThermoPol buffer New England Biolabs 
T4 DNA ligase T4 ligase buffer MBI Fermentas 
 
 
Miscellaneous 
 
Product Supplier 
21K human oligonucleotide array v.2.3 NMC 
6mm paper Whatman 
Cloning discs, 5mm Sigma-Aldrich 
DMEM Invitrogen 
Hybond P membrane GE Healthcare 
L-Glutamine Invitrogen 
Opti-MEM Invitrogen 
PBS Invitrogen 
Tet System Approved FBS Clontech 
Trypsine/EDTA Invitrogen 
 
 
Appendix II: Recipes 
 
Buffers and solutions  
 
All solutions used for microarray experiments were made with “Molecular biology grade 
water” from Eppendorf. For stock solutions and most buffers, double-distilled milliQ water 
was used, whereas normal distilled water was used for electrophoresis buffers and washing 
solutions such as TBS-T and SDS-PAGE electrophoresis buffer. 
 
APS 
5.0 g APS 
Dissolved in dH2O to 50 ml. 
 
Sterile filtered and stored in aliquots at -20 ºC. 
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0.5 M EDTA 
93.06 g Na2EDTA×2H2O (MW 372.24 g/mol)  
Dissolved in dH2O to about 400 ml. 
pH was adjusted to above 7 in order to dissolve the EDTA. 
After everything was dissolved the pH was adjusted to 8.0 with NaOH. 
Volume was adjusted to 500 ml with dH2O. 
 
Autoclaved. 
 
Freezing medium for mammalian cells 
25 ml FBS 
2.8 ml DMSO 
 
Stored at -20 ºC. 
 
1 M HCl 
2.6 ml 35 % HCl 
22.4 ml H2O 
 
Total volume 25 ml. 
 
Loading buffer agarose gel 
6 ml 85 % glycerol 
1 ml 0.5 M EDTA 
3 ml dH2O 
A few grains of bromophenol blue 
 
Stored in aliquots at -20 ºC. 
 
Minus(÷)-buffer 
500 ml Plus(+)-buffer 
2.62 g e-Amino-n-Caproic Acid (Sigma, A-7824) 
 
2.5 M NaAc pH 4.5 
10.25 g NaAc 
Dissolved in glacial acetic acid to pH 4.5. 
H2O to 50 ml. 
 
Sterile filtered. 
 
5M NaCl 
73.05 g NaCl 
H2O to 250 ml. 
 
Autoclaved. 
 
0.1 M NaOH 
10 M NaOH was diluted 1:100 to desired volume shortly before use. 
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10 M NaOH   
40 g NaOH pellets (MW 40 g/mol) 
H2O to 100 ml 
 
Autoclaved. 
 
Lower buffer (1.5 M Tris-HCl pH 8.8) 
90.83 g Tris base (MW 121.1 g/mol) 
dH2O to 400 ml 
pH was adjusted to 8.8 with concentrated HCl. 
Volume was adjusted to 500 ml with dH2O. 
 
Autoclaved. 
 
Plus(+)-buffer  
3 g Tris 
20 % methanol 
dH2O to 1 l 
 
10x Ponceau S 
5 ml Ponceau S 
10 ml acetic acid 
 dH2O to 100 ml 
 
Pre-hybridization solution 
1 g BSA fraction V dissolved in 70 ml H2O 
17.5 ml 20xSSC 
1 ml 10 % SDS 
H2O to 100 ml 
 
Made fresh for every day to be used, but may be stored a short period in the fridge.  
 
RIPA buffer 
150 mM NaCl 
1.0 % NP-40 
0.5 % Sodium deoxycholate 
0.1 % SDS 
50 mM Tris-HCl pH 8.0 
 
10 % SDS 
5.0 g SDS 
dH2O to 50 ml. 
 
3x SDS loading buffer 
6.0 ml 10 % SDS 
1.0 ml β-Mercaptoethanol 
5.0 ml 85 % Glycerol 
0.5 ml 0.5 M Tris-HCl pH 6.8 
A few grains of bromophenol blue. 
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Stored in fridge. 
 
10x SDS-PAGE electrophoresis buffer 
14.4 g Glycine 
3.06 g Tris base  
10 ml 10 % SDS  
dH2O to 1000 ml. 
 
20x SSC buffer 
175.3 g NaCl 
88.2 g Sodium citrate 
800 ml dH2O 
pH was adjusted to 7.0 with a few drops of 10 M NaOH. 
dH2O to 1000 ml. 
 
Stripping buffer 
100 mM β-Mercaptoetanol 
2% SDS 
62.5 mM Tris-HCl pH 6.7 
 
50x TAE buffer 
121 g Tris base (Tris[hydroxymetyl]aminometan)  
50 ml 0.5 M EDTA  
28.5 ml glacial acetic acid 
Volume was adjusted to 500 ml with dH2O. 
 
Autoclaved.  
 
10x TBS-T 
50 ml 1M Tris-HCl pH 8.0  
150 ml 5M NaCl  
2.5 ml Tween 20  
dH2O to 500 ml 
 
TBS-T with milk powder 
50 ml 10x TBS-T 
25 g dry milk powder 
dH2O to 500 ml 
 
TE buffer 
10 ml 1 M Tris-HCl, pH 8.0   
2 ml 0.5 M EDTA   
Volume was adjusted to 1000 ml with dH2O. 
 
Autoclaved. 
 
1M Tris-HCl, pH 8.0 
121.1 g Tris base  
Dissolved in dH2O to about 800 ml. 
pH was adjusted to 8.0 with concentrated HCl (approximately 45 ml). 
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Volume was adjusted to 1000 ml with dH2O. 
 
Autoclaved. 
 
Upper buffer (0.5 M Tris-HCl pH 6.8) 
30.28 g Tris base  
Dissolved in dH2O to 400 ml. 
pH was adjusted to 6.8 with concentrated HCl. 
Volume was adjusted to 500 ml with dH2O. 
 
Autoclaved. 
 
 
Gels 
 
0.9 % agarose gel 
0.54 g agarose 
60 ml TAE buffer 
Was heated in a microwave until all agarose was dissolved, then cooled down to about 50 °C 
before addition of 1-2 drops of EtBr.  
 
10 % SDS-PAGE gel (small) 
Separating gel (10 %) 
4 ml 40 % acrylamide C=2,7 
4 ml Lower buffer 
8 ml dH2O 
160 μl 10 % SDS 
50 μl APS 
10 μl TEMED 
 
Stacking gel (5 %) 
1.25 ml 40 % acrylamide C=2.7 
2.5 ml Upper buffer 
6.25 ml dH2O 
100 μl 10 % SDS 
30 μl APS 
10 μl TEMED 
 
 
Medium for bacteria 
 
LB-medium 
10 g Trypton 
5 g Yeast extract 
10 g NaCl 
H2O to 1000 ml 
pH was adjusted to 7.2 with 10M NaOH. 
 
Autoclaved. 
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Antibiotics were added if needed once the medium had cooled below 50 ºC. 
- Ampicillin, 100 mg/ml (1 ml 100 mg/ml to 1 l medium) 
- Chloramphenicol, 25 mg/ml (1 ml 25 mg/ml to 1 l medium) 
 
LB plates 
400 ml LB-medium (without antibiotics) 
6.0 g agar 
 
Autoclaved and cooled down to about 50 ºC. 
 
Antibiotics were added if needed (see recipe for LB-medium). 
Poured into petri dishes, about 20 ml per dish.  
 
 
Medium for mammalian cell cultures 
 
HEK293 Tet-On 
500 ml Dulbecco’s modified eagle medium (DMEM) 
50 ml FBS 
5 ml penicillin/streptomycin 
 
For non-transfected Tet-On cells geneticin was added to a final concentration of 100 μg/ml. 
Double stable cell lines were grown in medium with 100 μg/ml geneticin and 50 μg/ml 
hygromycin added. 
 
HEK293 Tet-Off 
500 ml Dulbecco’s modified eagle medium (DMEM) 
50 ml FBS 
5 ml penicillin/streptomycin 
 
Geneticin and hygromycin as for the Tet-On cells, but to the medium of double-stable cell 
lines Dox was added to a final concentration of 1 μg/ml every 48 hours.  
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Appendix III: Mw standards 
 
 “Precision Plus Protein 
Standards” from Bio-Rad.  
Used for SDS-PAGE. 
“1 Kb DNA Ladder” from 
Invitrogen/Life Technologies. 
Used for agarose gel 
electrophoresis.  
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Appendix IV: Sequences 
 
Primers used for PCR and sequencing 
 
C158: Forward primer for hcM-[1-443]-HA PCR-product 
5’-gactcagtgtcgaccATGGCCCGAAGACCCCGGCACAGC-3’ 
 
C177: Reverse primer for hcM-[1-443]-HA PCR-product 
5’-GAGTTTTCACAGTCTGGTCTCTATG-3’ 
 
S082: Forward primer for sequencing of pCIneo-hcM-[1-443]-HA 
5’-GACATCCACTTTGCCTTTCTCTCC-3’ 
 
S068: Reverse primer for sequencing of pCIneo-hcM-[1-443]-HA 
5’-GAGTTTTCACAGTCTGGTCTCTATG-3’ 
 
S078: Forward primer for sequencing of pTRE2hyg-hcM-[1-443]-HA 
5’-ccacgctgttttgacctccatagaag-3’ 
 
S079: Reverse primer for sequencing of pTRE2hyg-hcM-[1-443]-HA 
5’-tcccattctaaacaacaccctgaaaa-3’ 
 
 
Primers used for real-time RT-PCR 
 
v-MybAMV  
Forward (L035): 5’-TGgcgtcccctAATCG-3’ 
Reverse (L036): 5’-GGTTCTTGACAGCGTTAT-3’ 
 
c-Myb  
Forward (L001): 5’-AAATACGGTCCCCTGAAGATGCTA-3’ 
Reverse (L002): 5’-GTCTGCGTGAACAGTTGGGTATTC-3’ 
 
β-actin  
Forward (L003): 5’-GGGAAATCGTGCGTGACATT-3’ 
Reverse (L004): 5’-CAGGAAGGAAGGCTGGAAGA-3’ 
 
 
Sequence for human c-Myb 
 
Amino acid sequence of human c-Myb, deviations observed in c-Myb1-443 marked in yellow:  
 
MARRPRHSIY SSDEDDEDFE MCDHDYDGLL PKSGKRHLGK TRWTREEDEK 
LKKLVEQNGT DDWKVIANYL PNRTDVQCQH RWQKVLNPEL IKGPWTKEED 
QRVIELVQKY GPKRWSVIAK HLKGRIGKQC RERWHNHLNP EVKKTSWTEE 
EDRIIYQAHK RLGNRWAEIA KLLPGRTDNA IKNHWNSTMR RKVEQEGYLQ 
ESSKASQPAV ATSFQKNSHL MGFAQAPPTA QLPATGQPTV NNDYSYYHIS 
EAQNVSSHVP YPVALHVNIV NVPQPAAAAI QRHYNDEDPE KEKRIKELEL 
LLMSTENELK GQQVLPTQNH TCSYPGWHST TIADHTRPHG DSAPVSCLGE 
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HHSTPSLPAD PGSLPEESAS PARCMIVHQG TILDNVKNLL EFAETLQFID 
SFLNTSSNHE NSDLEMPSLT STPLIGHKLT VTTPFHRDQT VKTQKENTVF 
RTPAIKRSIL ESSPRTPTPF KHALAAQEIK YGPLKMLPQT PSHLVEDLQD 
VIKQESDESG IVAEFQENGP PLLKKIKQEV ESPTDKSGNF FCSHHWEGDS 
LNTQLFTQTS PVADAPNILT SSVLMAPASE DEDNVLKAFT VPKNRSLASP 
LQPCSSTWEP ASCGKMEEQM TSSSQARKYV NAFSARTLVM 
 
    
Appendix V: Plasmid maps 
This section lists the plasmids constructed in the work on this thesis as well as the plasmids 
and vectors from which they were derived. In the plasmid map presented here for pCIneo-
hcM[1-443]-HA the plasmid has been given the incorrect name of pCIneo-c-Myb-[1-443]-
HA. All maps with the exception of those for the vectors were created in Strider. 
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Appendix VI: Web page addresses 
 
Affymetrix www.affymetrix.com
Amersham  www.amersham.com
Applied Biosystems https://www2.appliedbiosystems.com/
ATCC cell database www.atcc.org
BASE (UiO) http://alba.uio.no/base
BASE homepage http://base.thep.lu.se
BD Biosciences www.bdbiosciences.com
Clontech www.clontech.com
Eppendorf www.eppendorf.com
Invitrogen www.invitrogen.com
MACF http://core.rr-research.no/index.php?section=8
MBI Fermentas www.fermentas.com
NanoDrop www.nanodrop.com/
New England Biolabs www.neb.com
NMC www.microarray.no
OMIA http://omia.angis.org.au/
OMIM www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM&itool=toolbar
PubMed www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
Qiagen www.qiagen.com/
Roche www.roche.com
Sigma-Aldrich www.sigmaaldrich.com
Stratagene www.stratagene.com
SYM www.rikshospitalet.no/sym
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